[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_987ddd06-5c53-46a5-80e5-83317b6202b8":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:987ddd06-5c53-46a5-80e5-83317b6202b8,\"}":41},{"code":4,"data":5,"meta":19},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":21,"manageAffiliations":22,"indexDatabases":23,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},"987ddd06-5c53-46a5-80e5-83317b6202b8","2023-12-05T06:19:22.432+00:00","2025-12-12T04:48:19.158+00:00",[],"SpringerPlus",{"issn":12,"title":14,"url":15},{"VOID":13},"21931801",{"EN":10},{"VOID":16},"https:\u002F\u002Flink.springer.com\u002Fjournal\u002F40064","PUBLISHER","PENDING",null,0,[],[],[24],{"id":25,"indexDatabase":26,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},"c0eb06b7-eee1-49bd-bdce-f364f715a07d",{"id":27,"createTime":28,"updateTime":29,"relativeEntities":30,"label":31,"description":33,"key":35,"publicationTags":36,"standard":19},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9","2023-05-22T09:57:18.509+00:00","2025-11-21T10:07:52.274+00:00",[],{"EN":32,"VI":32},"Scopus - Elsevier",{"EN":32,"VI":34},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[37],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F21100228569","2012-2017","SCOPUS__Q4",{"meta":42,"data":44},{"total":43},"3100",[45,165,302,454,528,661,739,820,1025,1245],{"id":46,"createTime":47,"updateTime":48,"relativeEntities":49,"slug":50,"properties":51,"entityType":60,"verifyStatus":61,"verifyTime":48,"verifyNote":62,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":63,"fullTextUrl":19,"authors":64,"publicationType":140,"publisherRelationship":141,"citationCount":19,"citationInfo":19,"publishDate":162,"publishYear":163,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"1f1ef02c-9b31-4b30-b382-52a596e72ed2","2023-12-27T08:36:13.301+00:00","2025-02-23T23:59:39.168+00:00",[],"Distribution-of-D-amino-acids-in-vinegars-and-involvement-of-lactic-acid-bacteria-in-the-production-of-D-amino-acids",{"references":52,"abstract":54,"title":56,"doi":58},{"VOID":53},"Abe H, Park JN, Fukumoto Y, Fujita E, Tanaka T, Washio T, Otsuka S, Shimizu T, Watanabe K: Occurrence of D -amino acids in fish sauces and other fermented fish products. Fish Sci 1999, 65: 637-641.\nAswad DW: Dtermination of D - and L -aspartate in amino acid mixture by high-performance liquid chromatography after derivatization with a chiral adduct of o -phthaldialdehyde. Anal Biochem 1984, 137: 405-409. 10.1016\u002F0003-2697(84)90106-4\nBrückner H, Hausch M: Gas chromatographic detection of D -amino acids as common constituents of fermented foods. Chromatographia 1989, 28: 487-492. 10.1007\u002FBF02261066\nBrückner H, Westhauser T: Chromatographic determination of L - and D -amino acids in plants. Amino Acids 2003, 24: 43-55.\nBrückner H, Becker D, Lüpke M: Chirality of amino acids of microorganisms used in food biotechnology. Chirality 1993, 5: 385-392. 10.1002\u002Fchir.530050521\nD’Aniello A, Vetere A, Petrucelli L: Further study on the specificity of D -amino acid oxidase and of D -aspartate oxidase and time course for complete oxidation of D -amino acids. Comp Biochem Physiol 1993, 105B: 731-734.\nErbe T, Brückner H: Chiral amino acid analysis of vinegars using gas chromatography selected ion monitoring mass spectrometry. Z Lebensm Unters Forsch A 1998, 207: 400-409. 10.1007\u002Fs002170050352\nErbe T, Brückner H: Chromatographic determination of amino acid enantiomers in beers and raw materials used for their manufacture. J Chromatogr A 2000, 881: 81-91. 10.1016\u002FS0021-9673(00)00255-7\nGogami Y, Okada K, Oikawa T: High-performance liquid chromatography analysis of naturally occurring D-amino acids in sake. J Chromatogr B 2011, 879: 3259-3267. 10.1016\u002Fj.jchromb.2011.04.006\nHashimoto A, Nishikawa T, Oka T, Takahashi K, Hayashi T: Determination of free amino acid enantiomers in rat brain and serum by high-performance liquid chromatography after derivatization with N -tert-butyloxycarbonyl- L -cysteine and o -phthaldialdehyde. J Chromatogr 1992, 582: 41-48. 10.1016\u002F0378-4347(92)80300-F\nJin D, Miyahara T, Oe T, Toyo’oka T: Determination of D -amino acids labeled with fluorescent chiral reagents, R (−)- and S (+)-4-(3-isothiocyanatopyrrolidin-1-yl)-7-( N , N -dimetylaminosulfonyl)-2, 1, 3,-benzoxadiazoles, in biological and food samples by liquid chromatography. Anal Biochem 1999, 269: 124-132. 10.1006\u002Fabio.1998.3090\nKato S, Ishihara T, Hemmi H, Kobayashi H, Yoshimura T: Alternations in D -amino acid concentrations and microbial community structures during the fermentation of red and white wines. J Biosci Bioeng 2011, 111: 104-108. 10.1016\u002Fj.jbiosc.2010.08.019\nKawai M, Sekine-Hayakawa Y, Okiyama A, Ninomiya Y: Gustatory sensation of L - and D -amino acids in humans. Amino Acids 2012, 43: 2349-2358. 10.1007\u002Fs00726-012-1315-x\nMachida M, Yamada O, Gomi K: Genomics of Aspergillus oryzae : learning from the history of Koji mold and exploration of its future. DNA Res 2008, 15: 173-183. 10.1093\u002Fdnares\u002Fdsn020\nOkada K, Gogami Y, Oikawa T: Principal component analysis of the relationship between the D -amino acid concentrations and the taste of the sake. Amino Acids 2013, 44: 489-498. 10.1007\u002Fs00726-012-1359-y\nRubio-Barroso S, Santos-Delgadoa MJ, Martín-Olivara C, Polo-Díeza LM: Indirect chiral HPLC determination and fluorimetric detection of D -amino acids in milk and oyster samples. J Dairy Sci 2006, 89: 82-89. 10.3168\u002Fjds.S0022-0302(06)72071-9\nSchiffman SS, Sennewwald K, Gagnon J: Comparison of taste qualities and thresholds of D - and L -amino acids. Physiol Behav 1981, 27: 51-59. 10.1016\u002F0031-9384(81)90298-5\nSolms J, Vuataz L, Egli RH: The taste of L - and D -amino acids. Experientia 1965, 21: 692-694. 10.1007\u002FBF02138474\nTosa T, Sano R, Chibata I: Immobilized D -amino acid oxidase preparation, some enzymatic properties, and potential uses. Agr Biol Chem 1974, 38: 1529-1534. 10.1271\u002Fbbb1961.38.1529",{"EN":55},"Levels of free D-amino acids were compared in 11 vinegars produced from different sources or through different manufacturing processes. To analyze the D- and L-amino acids, the enantiomers were initially converted into diastereomers using pre-column derivatization with o-phthaldialdehyde plus N-acethyl-L-cysteine or N-tert-butyloxycarbonyl-L-cysteine. This was followed by separation of the resultant fluorescent isoindol derivatives on an octadecylsilyl stationary phase using ultra-performance liquid chromatography. The analyses showed that the total D-amino acid level in lactic fermented tomato vinegar was very high. Furthermore, analysis of the amino acids in tomato juice samples collected after alcoholic, lactic and acetic fermentation during the production of lactic fermented tomato vinegar showed clearly that lactic fermentation is responsible for the D-amino acids production; marked increases in D-amino acids were seen during lactic fermentation, but not during alcoholic or acetic fermentation. This suggests lactic acid bacteria have a greater ability to produce D-amino acids than yeast or acetic acid bacteria.",{"EN":57},"Distribution of D-amino acids in vinegars and involvement of lactic acid bacteria in the production of D-amino acids",{"VOID":59},"10.1186\u002F2193-1801-2-691","PUBLICATION","VERIFIED","Auto Verify","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002F2193-1801-2-691",[65,83,98,114,127],{"id":66,"sortIndex":67,"researcher":19,"roles":68,"affiliations":70,"properties":80},"b3847d9b-1462-49c5-9fe9-ea6844e39058",2,[69],"AUTHOR",[71],{"id":19,"sortIndex":20,"affiliation":72,"properties":19},{"id":73,"createTime":74,"updateTime":74,"relativeEntities":75,"slug":19,"properties":76,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"c22ebe24-65ee-4759-8dd3-02a5f9b1796c","2023-12-27T08:36:13.337+00:00",[],{"title":77},{"VI":78},"Central Research Institute of Mizkan Group Corporation, Handa, Japan","AFFILIATION",{"title":81},{"VI":82},"Hirofumi Akano",{"id":84,"sortIndex":20,"researcher":19,"roles":85,"affiliations":86,"properties":95},"3828f7c7-7845-4608-840d-266fa42d03ee",[69],[87],{"id":19,"sortIndex":20,"affiliation":88,"properties":19},{"id":89,"createTime":90,"updateTime":90,"relativeEntities":91,"slug":19,"properties":92,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"5fe57afc-e11c-4e7a-a813-280f5067226d","2023-12-27T08:36:13.327+00:00",[],{"title":93},{"VI":94},"Department of Biomedical Engineering, Faculty of Engineering, Osaka Institute of Technology, Asahi-ku, Osaka, Japan",{"title":96},{"VI":97},"Yuta Mutaguchi",{"id":99,"sortIndex":100,"researcher":19,"roles":101,"affiliations":102,"properties":111},"4b0ea8ee-12e9-4af5-8420-adb5de0e1eb3",3,[69],[103],{"id":19,"sortIndex":20,"affiliation":104,"properties":19},{"id":105,"createTime":106,"updateTime":106,"relativeEntities":107,"slug":19,"properties":108,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"2644dd26-7486-4dad-bece-6ff27eb77783","2023-12-27T08:36:13.346+00:00",[],{"title":109},{"VI":110},"Microbial Genetic Division Institute of Genetic Resources Faculty of Agriculture, Kyushu University, Higashi-ku, Fukuoka, Japan",{"title":112},{"VI":113},"Katsumi Doi",{"id":115,"sortIndex":116,"researcher":19,"roles":117,"affiliations":118,"properties":124},"291e4667-a08e-41a1-be39-61c3ab3aa1dd",1,[69],[119],{"id":19,"sortIndex":20,"affiliation":120,"properties":19},{"id":89,"createTime":90,"updateTime":90,"relativeEntities":121,"slug":19,"properties":122,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":123},{"VI":94},{"title":125},{"VI":126},"Taketo Ohmori",{"id":128,"sortIndex":129,"researcher":19,"roles":130,"affiliations":131,"properties":137},"74fee7d7-ea00-43eb-91c7-204a36158c4c",4,[69],[132],{"id":19,"sortIndex":20,"affiliation":133,"properties":19},{"id":89,"createTime":90,"updateTime":90,"relativeEntities":134,"slug":19,"properties":135,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":136},{"VI":94},{"title":138},{"VI":139},"Toshihisa Ohshima","ARTICLE",{"url":63,"publisher":142,"properties":157},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":143,"slug":10,"properties":144,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":148,"manageAffiliations":149,"indexDatabases":150,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":145,"title":146,"url":147},{"VOID":13},{"EN":10},{"VOID":16},[],[],[151],{"id":25,"indexDatabase":152,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":153,"label":154,"description":155,"key":35,"publicationTags":156,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":158,"pages":160},{"VOID":159},"2",{"VOID":161},"1-9","2013-12-27",2013,false,{"id":166,"createTime":167,"updateTime":168,"relativeEntities":169,"slug":170,"properties":171,"entityType":60,"verifyStatus":61,"verifyTime":168,"verifyNote":62,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":180,"fullTextUrl":19,"authors":181,"publicationType":140,"publisherRelationship":280,"citationCount":19,"citationInfo":19,"publishDate":300,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"dd78625c-3fd2-4e20-81a8-4b0b51b3cd4e","2024-01-15T11:24:12.767+00:00","2024-09-13T23:58:44.784+00:00",[],"Evaluation-of-the-recurrence-pattern-of-gastric-cancer-after-laparoscopic-gastrectomy-with-D2-lymphadenectomy",{"references":172,"abstract":174,"title":176,"doi":178},{"VOID":173},"Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T et al (2012) Risk factors for peritoneal recurrence in stage II\u002FIII gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy. Ann Surg Oncol 19:1568–1574\nCai J, Wei D, Gao CF, Zhang CS, Zhang H, Zhao T (2011) A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer. Dig Surg 28:331–337\nD’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS (2004) Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 240:808–816\nDegiuli M, Sasako M, Ponti A (2010) Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer. Br J Surg 97:643–649\nHuang YL, Lin HG, Yang JW, Jiang FQ, Zhang T, Yang HM et al (2014) Laparoscopy-assisted versus open gastrectomy with D2 lymph node dissection for advanced gastric cancer: a meta-analysis. Int J Clin Exp Med 7:1490–1499\nHuscher CG, Mingoli A, Sgarzini G, Sansonetti A, Di Paola M, Recher A et al (2005) Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: five-year results of a randomized prospective trial. Ann Surg 241:232–237\nIm WJ, Kim MG, Ha TK, Kwon SJ (2012) Tumor size as a prognostic factor in gastric cancer patient. J Gastric Cancer 12:164–172\nIsobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I et al (2011) Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer 14:301–316\nJapanese Gastric Cancer Association (2011a) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112\nJapanese Gastric Cancer Association (2011b) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14:113–123\nKatai H, Sasako M, Fukuda H, Nakamura K, Hiki N, Saka M et al (2010) JCOG Gastric Cancer Surgical Study Group. Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG 0703). Gastric Cancer 13:238–244\nKim SJ, Kim HH, Kim YH, Hwang SH, Lee HS, Park do J et al (2009) Peritoneal metastasis: detection with 16- or 64-detector row CT in patients undergoing surgery for gastric cancer. Radiology 253:407–415\nKim HH, Hyung WJ, Cho GS, Kim MC, Han SU, Kim W et al (2010) Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report—a phase III multicenter, prospective, randomized Trial (KLASS Trial). Ann Surg 251:417–420\nKim KH, Kim MC, Jung GJ, Kim HH (2012) Long-term outcomes and feasibility with laparoscopy-assisted gastrectomy for gastric cancer. J Gastric Cancer 12:18–25\nKitano S, Iso Y, Moriyama M, Suqimachi K (1994) Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 4:146–148\nLee CM, Jee YS, Lee JH, Son SY, Ahn SH, Park do J et al (2014a) Length of negative resection margin does not affect local recurrence and survival in the patients with gastric cancer. World J Gastroenterol 20:10518–10524\nLee JH, Son SY, Lee CM, Ahn SH, Park do J, Kim HH (2014b) Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer 17:529–536\nMaruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H et al (2006) Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 9:51–66\nNakauchi M, Suda K, Kadoya S, Inaba K, Ishida Y, Uyama I (2015) Technical aspects and short- and long-term outcomes of totally laparoscopic total gastrectomy for advanced gastric cancer: a single-institution retrospective study. Surg Endosc. 2015 Dec 24. [Epub ahead of print]. PMID: 26703126\nOtsuji E, Kuriu Y, Ichikawa D, Okamoto K, Ochiai T, Hagiwara A et al (2004) Time to death and pattern of death in recurrence following curative resection of gastric carcinoma: analysis based on depth of invasion. World J Surg 28:866–869\nSakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A et al (2007) ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820\nSasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A et al (2008) Japan Clinical Oncology Group. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359:453–462\nShim JH, Yoo HM, Lee HH, Kim JG, Jeon HM, Song KY et al (2011) Use of laparoscopy as an alternative to computed tomography (CT) and positron emission tomography (PET) scans for the detection of recurrence in patients with gastric cancer: a pilot study. Surg Endosc 25:3338–3344\nShinohara T, Satoh S, Kanaya S, Ishida Y, Taniguchi K, Isogaki J et al (2013) Laparoscopic versus open D2 gastrectomy for advanced gastric cancer: a retrospective cohort study. Surg Endosc 27:286–294\nSongun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomized nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449\nSuda K, Man-I M, Ishida Y, Kawamura Y, Satoh S, Uyama I (2015) Potential advantages of robotic radical gastrectomy for gastric adenocarcinoma in comparison with conventional laparoscopic approach: a single institutional retrospective comparative cohort study. Surg Endosc 29:673–685\nTajima Y, Yamazaki K, Nishino N, Morohara K, Yamazaki T, Kaetsu T et al (2004) Gastric and intestinal phenotypic marker expression in gastric carcinomas and recurrence pattern after surgery-immunohistochemical analysis of 213 lesions. Br J Cancer 91:1342–1348\nUyama I, Sugioka A, Fujita J, Komori Y, Matsui H, Soga R et al (1999a) Completely laparoscopic extraperigastric lymph node dissection for gastric malignancies located in the middle or lower third of the stomach. Gastric Cancer 2:186–190\nUyama I, Sugioka A, Fujita J, Komori Y, Matsui H, Hasumi A (1999b) Laparoscopic total gastrectomy with distal pancreatosplenectomy and D2 lymphadenectomy for advanced gastric cancer. Gastric Cancer 2:230–234\nYoshimura F, Inaba K, Kawamura Y, Ishida Y, Taniguchi K, Isogaki J et al (2011) Clinical outcome and clinicopathological characteristics of recurrence after laparoscopic gastrectomy for advanced gastric cancer. Digestion 83:184–190\nZeng YK, Yang ZL, Peng JS, Lin HS, Cai L (2012) Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 256:39–52\nZou ZH, Zhao LY, Mou TY, Hu YF, Yu J, Liu H et al (2014) Laparoscopic vs open D2 gastrectomy for locally advanced gastric cancer: a meta-analysis. World J Gastroenterol 20:16750–16764",{"EN":175},"The aim of this study was to analyze the oncological aspects of gastric cancer following laparoscopic gastrectomy with D2 lymphadenectomy (LG-D2). We retrospectively evaluated the long-term outcomes of 354 patients who underwent LG-D2 for primary gastric cancer. Recurrence patterns and predictors of peritoneal metastasis were analyzed. Median follow-up time was 43.8 months. Five-year overall survival rates for yp\u002FpStages I, II, and III gastric cancer were 93.7, 78.5, and 42.2 %, respectively. Recurrence was observed in 86 patients. Peritoneal metastasis was the most frequent recurrence pattern (n = 51), followed by hepatic metastasis (n = 17). Lymphatic recurrence at distant sites was observed in 10 patients. No locoregional lymph node metastasis or local recurrence was seen. Nine of 51 cases of peritoneal recurrence were detected by probe laparoscopy. Peritoneal recurrence rates were significantly higher in yp\u002FpT4 and yp\u002FpN3 diseases compared with yp\u002FpT ≤ 3 and yp\u002FpN ≤ 2 diseases. Multivariate analyses demonstrated that yp\u002FpT4, yp\u002FpN3, tumor size ≥70 mm, vascular invasion, and undifferentiated tumors were predictors of peritoneal recurrence following LG-D2. Long-term outcomes of gastric cancer following LG-D2, including recurrence patterns and predictors of peritoneal metastasis, were comparable to those following open D2 gastrectomy. LG-D2 showed good local control. Probe laparoscopy after LG may be effective in detecting peritoneal recurrence, which is not determined with less invasive examinations, including a CT scan. Future large-scale prospective studies are desirable to evaluate not only surgical but also oncological benefits and safety of LG-D2 for advanced gastric cancer.",{"EN":177},"Evaluation of the recurrence pattern of gastric cancer after laparoscopic gastrectomy with D2 lymphadenectomy",{"VOID":179},"10.1186\u002Fs40064-016-2535-4","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-016-2535-4",[182,197,221,243,256,268],{"id":183,"sortIndex":129,"researcher":19,"roles":184,"affiliations":185,"properties":194},"d79fba34-65f0-4999-a793-4138f89ef85e",[69],[186],{"id":19,"sortIndex":20,"affiliation":187,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":190,"slug":19,"properties":191,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"e18d402e-819e-44af-8300-b878cfa5ba1f","2024-02-07T13:04:51.584+00:00",[],{"title":192},{"VI":193},"Division of Upper GI, Department of Surgery, Fujita Health University, Toyoake, Japan",{"title":195},{"VI":196},"Koichi Suda",{"id":198,"sortIndex":20,"researcher":19,"roles":199,"affiliations":200,"properties":218},"f9c577d8-7b13-4357-89fd-f2c2352e4916",[69],[201,206],{"id":19,"sortIndex":20,"affiliation":202,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":203,"slug":19,"properties":204,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":205},{"VI":193},{"id":207,"sortIndex":116,"affiliation":208,"properties":217},"b9307832-d50c-47a2-a314-e0b21f72a387",{"id":209,"createTime":210,"updateTime":211,"relativeEntities":212,"slug":213,"properties":214,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"06f9666d-8398-43eb-abea-256fb72e758b","2024-01-15T11:24:12.793+00:00","2025-06-11T20:01:42.405+00:00",[],"Department-of-Surgery-Kokura-Memorial-Hospital-Kitakyusyu-Japan",{"title":215},{"VI":216},"Department of Surgery, Kokura Memorial Hospital, Kitakyusyu, Japan",{},{"title":219},{"VI":220},"Yuichiro Kawamura",{"id":222,"sortIndex":116,"researcher":19,"roles":223,"affiliations":224,"properties":240},"c7ded3ac-bdf4-4d76-a8cf-db8d71ed8708",[69],[225,235],{"id":226,"sortIndex":116,"affiliation":227,"properties":234},"00f58d4e-b9d2-48cb-bd01-2f94129ec1df",{"id":228,"createTime":229,"updateTime":229,"relativeEntities":230,"slug":19,"properties":231,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"104fef57-af8c-4a00-85ee-6bfdb8df8ed7","2023-12-13T12:49:49.032+00:00",[],{"title":232},{"VI":233},"Department of Surgery, National Hospital Organization, Himeji Medical Center, Himeji, Japan",{},{"id":19,"sortIndex":20,"affiliation":236,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":237,"slug":19,"properties":238,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":239},{"VI":193},{"title":241},{"VI":242},"Seiji Satoh",{"id":244,"sortIndex":245,"researcher":19,"roles":246,"affiliations":247,"properties":253},"d93b2f4a-8d8b-4a38-99d7-ad85b4ceb263",5,[69],[248],{"id":19,"sortIndex":20,"affiliation":249,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":250,"slug":19,"properties":251,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":252},{"VI":193},{"title":254},{"VI":255},"Ichiro Uyama",{"id":257,"sortIndex":100,"researcher":19,"roles":258,"affiliations":259,"properties":265},"91924067-f3a4-4778-bc70-632a95ac242a",[69],[260],{"id":19,"sortIndex":20,"affiliation":261,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":262,"slug":19,"properties":263,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":264},{"VI":193},{"title":266},{"VI":267},"Yoshinori Ishida",{"id":269,"sortIndex":67,"researcher":19,"roles":270,"affiliations":271,"properties":277},"8a153336-df9f-4b49-b4ff-000710148802",[69],[272],{"id":19,"sortIndex":20,"affiliation":273,"properties":19},{"id":188,"createTime":189,"updateTime":189,"relativeEntities":274,"slug":19,"properties":275,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":276},{"VI":193},{"title":278},{"VI":279},"Yusuke Umeki",{"url":180,"publisher":281,"properties":296},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":282,"slug":10,"properties":283,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":287,"manageAffiliations":288,"indexDatabases":289,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":284,"title":285,"url":286},{"VOID":13},{"EN":10},{"VOID":16},[],[],[290],{"id":25,"indexDatabase":291,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":292,"label":293,"description":294,"key":35,"publicationTags":295,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":297,"pages":299},{"VOID":298},"5",{"VOID":161},"2016-06-21",2016,{"id":303,"createTime":304,"updateTime":304,"relativeEntities":305,"slug":19,"properties":306,"entityType":60,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":315,"fullTextUrl":19,"authors":316,"publicationType":140,"publisherRelationship":431,"citationCount":19,"citationInfo":19,"publishDate":452,"publishYear":453,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"f5ad198c-c617-4382-bb3a-9d34625f8e42","2024-01-12T23:58:31.930+00:00",[],{"references":307,"abstract":309,"title":311,"doi":313},{"VOID":308},"Ball C, Thomson KR, Kavnoudias H (2010) Irreversible electroporation: a new challenge in “out of operating theater” anesthesia. Anesth Analg 110:1305–1309\nCannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd (2013) Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107:544–549\nChoi JW, Lu DS, Osuagwu F, Raman S, Lassman C (2014) Assessment of chronological effects of irreversible electroporation on hilar bile ducts in a porcine model. Cardiovasc Intervent Radiol 37:224–230\nDavalos RV, Mir IL, Rubinsky B (2005) Tissue ablation with irreversible electroporation. Ann Biomed Eng 33:223–231\nDeodhar A, Dickfeld T, Single GW, Hamilton WC Jr, Thornton RH, Sofocleous CT, Maybody M, Gónen M, Rubinsky B, Solomon SB (2011) Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. AJR Am J Roentgenol 196:W330–W335\nRubinsky B, Onik G, Mikus P (2007) Irreversible electroporation: a new ablation modality—clinical implications. Technol Cancer Res Treat 6:37–48\nScheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, Meijer S, van Kuijk C, van den Tol PM, Meijerink MR (2014) Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol 25:997–1011\nSchoellnast H, Monette S, Ezell PC, Maybody M, Erinjeri JP, Stubblefield MD, Single G, Solomon SB (2013a) The delayed effects of irreversible electroporation ablation on nerves. Eur Radiol 23:375–380\nSchoellnast H, Monette S, Ezell PC, Single G, Maybody M, Weiser MR, Fong Y, Solomon SB (2013b) Irreversible electroporation adjacent to the rectum: evaluation of pathological effects in a pig model. Cardiovasc Intervent Radiol 36:213–220\nThomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, Roberts S, Evans P, Ball C, Haydon A (2011) Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol 22:611–621",{"EN":310},"Irreversible electroporation (IRE) is a promising technique for the focal treatment of soft tissue tumors. Even though the local application of an excessive electric field is a potential cause of cardiac arrhythmias, initial clinical studies have shown that IRE is generally safe when cardiac gating is employed. In this case report, we observed an episode of ventricular extrasystoles without hemodynamic changes during which time the synchronization device failed to operate properly, with pulses delivered not in the absolute refractory period but in the relative refractory period. At present, persons performing IRE must keep in mind that there is a small but real risk of synchronization failure even when a cardiac synchronization device is used. It is advisable to err on the side of caution when treating lesions near the heart.",{"EN":312},"Case study to assess the safety of irreversible electroporation near the heart",{"VOID":314},"10.1186\u002Fs40064-015-0828-7","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-015-0828-7",[317,333,345,357,370,383,395,407,419],{"id":318,"sortIndex":319,"researcher":19,"roles":320,"affiliations":321,"properties":330},"261396b3-2ca4-41d3-aa49-47d02e860aba",6,[69],[322],{"id":19,"sortIndex":20,"affiliation":323,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":326,"slug":19,"properties":327,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"497b1e46-1fb8-4deb-8786-2a5d9abe23fd","2024-01-13T14:21:25.576+00:00",[],{"title":328},{"VI":329},"Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Japan",{"title":331},{"VI":332},"Yoshihiro Furuichi",{"id":334,"sortIndex":245,"researcher":19,"roles":335,"affiliations":336,"properties":342},"6184de4c-3318-484d-8fbd-6e8fae817f16",[69],[337],{"id":19,"sortIndex":20,"affiliation":338,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":339,"slug":19,"properties":340,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":341},{"VI":329},{"title":343},{"VI":344},"Toshifumi Mori",{"id":346,"sortIndex":116,"researcher":19,"roles":347,"affiliations":348,"properties":354},"e8c1e7e8-64b2-4d77-9d7b-990c6efda55b",[69],[349],{"id":19,"sortIndex":20,"affiliation":350,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":351,"slug":19,"properties":352,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":353},{"VI":329},{"title":355},{"VI":356},"Fuminori Moriyasu",{"id":358,"sortIndex":359,"researcher":19,"roles":360,"affiliations":361,"properties":367},"a2e2e951-69d4-4892-8ba1-8d23db268b5b",7,[69],[362],{"id":19,"sortIndex":20,"affiliation":363,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":364,"slug":19,"properties":365,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":366},{"VI":329},{"title":368},{"VI":369},"Yoshiyuki Kobayashi",{"id":371,"sortIndex":372,"researcher":19,"roles":373,"affiliations":374,"properties":380},"cf393972-d2ff-44b2-a786-fcd0e5af26f6",8,[69],[375],{"id":19,"sortIndex":20,"affiliation":376,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":377,"slug":19,"properties":378,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":379},{"VI":329},{"title":381},{"VI":382},"Ikuo Nakamura",{"id":384,"sortIndex":100,"researcher":19,"roles":385,"affiliations":386,"properties":392},"7fbb7c3d-531a-4e1a-b843-8be6875ab294",[69],[387],{"id":19,"sortIndex":20,"affiliation":388,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":389,"slug":19,"properties":390,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":391},{"VI":329},{"title":393},{"VI":394},"Mayumi Ando",{"id":396,"sortIndex":20,"researcher":19,"roles":397,"affiliations":398,"properties":404},"cc8e5309-0c5a-4c51-a36c-b689f6f3d1c6",[69],[399],{"id":19,"sortIndex":20,"affiliation":400,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":401,"slug":19,"properties":402,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":403},{"VI":329},{"title":405},{"VI":406},"Katsutoshi Sugimoto",{"id":408,"sortIndex":67,"researcher":19,"roles":409,"affiliations":410,"properties":416},"d49e84b9-7f4b-48da-ba70-c893d053c118",[69],[411],{"id":19,"sortIndex":20,"affiliation":412,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":413,"slug":19,"properties":414,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":415},{"VI":329},{"title":417},{"VI":418},"Hirohito Takeuchi",{"id":420,"sortIndex":129,"researcher":19,"roles":421,"affiliations":422,"properties":428},"fb41fc42-e113-41e8-a735-f401d7b83393",[69],[423],{"id":19,"sortIndex":20,"affiliation":424,"properties":19},{"id":324,"createTime":325,"updateTime":325,"relativeEntities":425,"slug":19,"properties":426,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":427},{"VI":329},{"title":429},{"VI":430},"Takatomo Sano",{"url":315,"publisher":432,"properties":447},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":433,"slug":10,"properties":434,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":438,"manageAffiliations":439,"indexDatabases":440,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":435,"title":436,"url":437},{"VOID":13},{"EN":10},{"VOID":16},[],[],[441],{"id":25,"indexDatabase":442,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":443,"label":444,"description":445,"key":35,"publicationTags":446,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":448,"pages":450},{"VOID":449},"4",{"VOID":451},"1-4","2015-02-11",2015,{"id":455,"createTime":456,"updateTime":456,"relativeEntities":457,"slug":19,"properties":458,"entityType":60,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":467,"fullTextUrl":19,"authors":468,"publicationType":140,"publisherRelationship":508,"citationCount":19,"citationInfo":19,"publishDate":527,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"c9022558-d371-4922-bd82-cffe709343af","2024-02-05T23:57:48.805+00:00",[],{"references":459,"abstract":461,"title":463,"doi":465},{"VOID":460},"Antal AD, Cikirikcioglu M, Myers PO, Didier D, Kalangos A (2010) Respiratory distress after surgery of RVOT pathologies: a word of caution on pseudoaneurysm development. Thorac Cardiovasc Surg 58(6):356–358\nCheatham SL, Holzer RJ, Chisolm JL, Cheatham JP (2013) The Medtronic Melody(R) transcatheter pulmonary valve implanted at 24-mm diameter—it works. Catheter Cardiovasc Interv 82(5):816–823\nCools B, Brown SC, Heying R et al (2015) Percutaneous pulmonary valve implantation for free pulmonary regurgitation following conduit-free surgery of the right ventricular outflow tract. Int J Cardiol 186:129–135\nFeltes TF, Bacha E, Beekman RH 3rd et al (2011) Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation 123(22):2607–2652\nHolzer RJ, Hijazi ZM (2016) Transcatheter pulmonary valve replacement: state of the art. Catheter Cardiovasc Interv 87(1):117–128\nJagia P, Sharma S, Juneja R, Guleria R (2011) Transcatheter treatment of pulmonary artery pseudoaneurysm using a PDA closure device. Diagn Interv Radiol 17(1):92–94\nLevine JC, Mayer JE Jr, Keane JF, Spevak PJ, Sanders SP (1995) Anastomotic pseudoaneurysm of the ventricle after homograft placement in children. Ann Thorac Surg 59(1):60–66\nMasri SI, Majdalani MN, Bitar FF (2014) Novel percutaneous femoral arterial-transthoracic approach for closure of ascending aortic pseudoaneurysm with a septal occluder device in a child. Cardiol Young 24(4):752–755\nMurashita T, Hatta E, Imamura M, Yasuda K (2002) Giant pseudoaneurysm of the right ventricular outflow tract after repair of truncus arteriosus: evaluation by MR imaging and surgical approach. Eur J Cardiothorac Surg 22(5):849–851\nSadiq M, Fenton AC, Firmin RK (1994) False aneurysm of the right ventricular outflow tract after total correction of tetralogy of Fallot: diagnosis by echocardiography and successful repair by neck cannulation for cardiopulmonary bypass. Br Heart J 71(6):566–568\nVaidyanathan B, Kannan BR, Kumar RK (2004) Images in cardiovascular medicine. Catheter closure of pseudoaneurysm of the main pulmonary artery. Circulation 110(13):e322–e323\nYeo TC, Malouf JF, Oh JK, Seward JB (1998) Clinical profile and outcome in 52 patients with cardiac pseudoaneurysm. Ann Intern Med 128(4):299–305",{"EN":462},"Pseudoaneurysm formation is a rare but potentially life-threatening complication after surgical repair of congenital heart disease. We present a boy with truncus arteriosus communis 14 years after homograft placement in pulmonary position. On follow-up, he presented progressive chronic homograft degeneration. Moreover, a large pseudoaneurysm in the right ventricular outflow tract was surprisingly depicted. We opted for a two-stage interventional approach.",{"EN":464},"Dysfunctional pulmonary artery conduit and co-existing large pseudoaneurysm: well-suited for a percutaneous approach with the Melody valve?",{"VOID":466},"10.1186\u002Fs40064-016-3273-3","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-016-3273-3",[469,484,496],{"id":470,"sortIndex":116,"researcher":19,"roles":471,"affiliations":472,"properties":481},"bfd066b4-6c17-43ad-84d4-78be459af871",[69],[473],{"id":19,"sortIndex":20,"affiliation":474,"properties":19},{"id":475,"createTime":476,"updateTime":476,"relativeEntities":477,"slug":19,"properties":478,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"e3bcb118-0ed6-40a4-889c-327bf4e168c6","2024-02-05T23:57:48.820+00:00",[],{"title":479},{"VI":480},"Department of Congenital Heart Defects and Pediatric Cardiology, Heart Center, University of Freiburg, Freiburg, Germany",{"title":482},{"VI":483},"Brigitte Stiller",{"id":485,"sortIndex":67,"researcher":19,"roles":486,"affiliations":487,"properties":493},"ddf1d0af-b29e-4e37-ab00-19f3761ae4fa",[69],[488],{"id":19,"sortIndex":20,"affiliation":489,"properties":19},{"id":475,"createTime":476,"updateTime":476,"relativeEntities":490,"slug":19,"properties":491,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":492},{"VI":480},{"title":494},{"VI":495},"Jochen Grohmann",{"id":497,"sortIndex":20,"researcher":19,"roles":498,"affiliations":499,"properties":505},"050f75e5-acb6-4ce4-8d32-b8ba21c66fff",[69],[500],{"id":19,"sortIndex":20,"affiliation":501,"properties":19},{"id":475,"createTime":476,"updateTime":476,"relativeEntities":502,"slug":19,"properties":503,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":504},{"VI":480},{"title":506},{"VI":507},"Rouven Kubicki",{"url":467,"publisher":509,"properties":524},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":510,"slug":10,"properties":511,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":515,"manageAffiliations":516,"indexDatabases":517,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":512,"title":513,"url":514},{"VOID":13},{"EN":10},{"VOID":16},[],[],[518],{"id":25,"indexDatabase":519,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":520,"label":521,"description":522,"key":35,"publicationTags":523,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":525,"pages":526},{"VOID":298},{"VOID":451},"2016-09-15",{"id":529,"createTime":530,"updateTime":531,"relativeEntities":532,"slug":533,"properties":534,"entityType":60,"verifyStatus":61,"verifyTime":531,"verifyNote":62,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":543,"fullTextUrl":19,"authors":544,"publicationType":140,"publisherRelationship":640,"citationCount":19,"citationInfo":19,"publishDate":660,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"033f6917-8afd-4884-8ee2-17655f3d588e","2023-12-25T21:57:23.001+00:00","2024-12-24T23:57:27.353+00:00",[],"Bronchospasm-in-obese-patients-undergoing-elective-laparoscopic-surgery-under-general-anesthesia",{"references":535,"abstract":537,"title":539,"doi":541},{"VOID":536},"Aaron SD, Fergusson D, Dent R, Chen Y, Vandemheen KL, Dales RE (2004) Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest 125(6):2046–2052\nAdams JP, Murphy PG (2000) Obesity in anaesthesia and intensive care. Br J Anaesth 85(1):91–108\nBeuther DA, Sutherland ER (2007) Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 175(7):661–666\nBjerkedal T (1957) Overweight and hypertension. Acta Med Scand 159(1):13–26\nBlumberg MZ (1973) Morphine for severe asthma? N Engl J Med 288(1):50\nCamargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE (1999) Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 159(21):2582–2588\nChen H, Tliba O, Van Besien CR, Panettieri RA Jr, Amrani Y (2003) TNF-[alpha] modulates murine tracheal rings responsiveness to G-protein-coupled receptor agonists and KCl. J Appl Physiol (1985) 95(2):864–872\nChoban PS, Flancbaum L (1997) The impact of obesity on surgical outcomes: a review. J Am Coll Surg 185(6):593–603\nChung F, Mezei G, Tong D (1999) Pre-existing medical conditions as predictors of adverse events in day-case surgery. Br J Anaesth 83(2):262–270\nDamia G, Mascheroni D, Croci M, Tarenzi L (1988) Perioperative changes in functional residual capacity in morbidly obese patients. Br J Anaesth 60(5):574–578\nDindo D, Muller MK, Weber M, Clavien PA (2003) Obesity in general elective surgery. Lancet 361(9374):2032–2035\nDing DJ, Martin JG, Macklem PT (1987) Effects of lung volume on maximal methacholine-induced bronchoconstriction in normal humans. J Appl Physiol (1985) 62(3):1324–1330\nDixon JB, Chapman L, O’Brien P (1999) Marked improvement in asthma after Lap-Band surgery for morbid obesity. Obes Surg 9(4):385–389\nDuncan PG, Cohen MM, Tweed WA, Biehl D, Pope WD, Merchant RN, DeBoer D (1992) The Canadian four-centre study of anaesthetic outcomes: III. Are anaesthetic complications predictable in day surgical practice? Can J Anaesth 39(5 Pt 1):440–448\nEl-Metainy S, Ghoneim T, Aridae E, Abdel Wahab M (2011) Incidence of perioperative adverse events in obese children undergoing elective general surgery. Br J Anaesth 106(3):359–363\nEschenbacher WL, Bethel RA, Boushey HA, Sheppard D (1984) Morphine sulfate inhibits bronchoconstriction in subjects with mild asthma whose responses are inhibited by atropine. Am Rev Respir Dis 130(3):363–367\nFredberg JJ (2000) Frozen objects: small airways, big breaths, and asthma. J Allergy Clin Immunol 106(4):615–624\nGuerra S, Wright AL, Morgan WJ, Sherrill DL, Holberg CJ, Martinez FD (2004) Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. Am J Respir Crit Care Med 170(1):78–85\nGump A, Haughney L, Fredberg J (2001) Relaxation of activated airway smooth muscle: relative potency of isoproterenol vs. tidal stretch. J Appl Physiol (1985) 90(6):2306–2310\nHerrara MF, Lozano-Salazar RR, Gonzalez-Barranco J, Rull JA (1999) Diseases and problems secondary to massive obesity. Eur J Gastroenterol Hepatol 11(2):63–67\nHofer RE, Kai T, Decker PA, Warner DO (2008) Obesity as a risk factor for unanticipated admissions after ambulatory surgery. Mayo Clin Proc 83(8):908–916\nHotamisligil GS (2003) Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27(Suppl 3):S53–S55\nKim S, Camargo CA Jr (2003) Sex-race differences in the relationship between obesity and asthma: the behavioral risk factor surveillance system, 2000. Ann Epidemiol 13(10):666–673\nLitonjua AA, Sparrow D, Celedon JC, DeMolles D, Weiss ST (2002) Association of body mass index with the development of methacholine airway hyperresponsiveness in men: the Normative Aging Study. Thorax 57(7):581–585\nLuder E, Ehrlich RI, Lou WY, Melnik TA, Kattan M (2004) Body mass index and the risk of asthma in adults. Respir Med 98(1):29–37\nMacgregor AM, Rand CS (1993) Gastric surgery in morbid obesity. Outcome in patients aged 55 years and older. Arch Surg 128(10):1153–1157\nNawrocki AR, Scherer PE (2004) The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharmacol 4(3):281–289\nNightingale CE, Margarson MP, Shearer E, Redman JW, Lucas DN, Cousins JM, Fox WT, Kennedy NJ, Venn PJ, Skues M et al (2015) Peri-operative management of the obese surgical patient 2015: Association of Anaesthetists of Great Britain and Ireland Society for Obesity and Bariatric Anaesthesia. Anaesthesia 70(7):859–876\nOtulana B, Okikawa J, Linn L, Morishige R, Thipphawong J (2004) Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. Int J Clin Pharmacol Ther 42(8):456–462\nPelosi P, Croci M, Ravagnan I, Cerisara M, Vicardi P, Lissoni A, Gattinoni L (1997) Respiratory system mechanics in sedated, paralyzed, morbidly obese patients. J Appl Physiol (1985) 82(3):811–818\nRajala MW, Scherer PE (2003) Minireview: the adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144(9):3765–3773\nRutherford RM, Azher T, Gilmartin JJ (2002) Dramatic response to nebulized morphine in an asthmatic patient with severe chronic cough. Ir Med J 95(4):113–114\nSampson MG, Grassino AE (1983) Load compensation in obese patients during quiet tidal breathing. J Appl Physiol Respir Environ Exerc Physiol 55(4):1269–1276\nSchachter LM, Salome CM, Peat JK, Woolcock AJ (2001) Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax 56(1):4–8\nShenkman Z, Shir Y, Brodsky JB (1993) Perioperative management of the obese patient. Br J Anaesth 70(3):349–359\nShore SA, Fredberg JJ (2005) Obesity, smooth muscle, and airway hyperresponsiveness. J Allergy Clin Immunol 115(5):925–927\nShore SA, Rivera-Sanchez YM, Schwartzman IN, Johnston RA (2003) Responses to ozone are increased in obese mice. J Appl Physiol (1985) 95(3):938–945\nSoleymani Y, Weiss NS, Sinnott EC, Goldzier S (1972) Management of life-threatening asthma in children. A preliminary study of the use of morphine in respiratory failure. Am J Dis Child 123(6):533–540\nStenqvist O, Sonander H, Nilsson K (1979) Small endotracheal tubes: ventilator and intratracheal pressures during controlled ventilation. Br J Anaesth 51(4):375–381\nThe Association of Anaesthetists of Great Britain and Ireland (2007) Peri-operative management of the morbidly obese patient. London, UK, pp 1–13\nThomas EJ, Goldman L, Mangione CM, Marcantonio ER, Cook EF, Ludwig L, Sugarbaker D, Poss R, Donaldson M, Lee TH (1997) Body mass index as a correlate of postoperative complications and resource utilization. Am J Med 102(3):277–283\nThomson CC, Clark S, Camargo CA Jr (2003) Body mass index and asthma severity among adults presenting to the emergency department. Chest 124(3):795–802\nWarner DO (2006) Perioperative abstinence from cigarettes: physiologic and clinical consequences. Anesthesiology 104(2):356-367\nWatcha MF, White PF (1992) Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 77(1):162–184\nWeiss ST, Shore S (2004) Obesity and asthma: directions for research. Am J Respir Crit Care Med 169(8):963–968\nYap JC, Watson RA, Gilbey S, Pride NB (1995) Effects of posture on respiratory mechanics in obesity. J Appl Physiol (1985) 79(4):1199–1205",{"EN":538},"Existing data suggest that obesity correlates with airway hyper-reactivity. However, the incidence of bronchospasm during bariatric surgery in obese patients has not been well studied. \nThis was a prospective observational study comparing 50 obese versus 50 non obese patients undergoing elective laparoscopic surgery over a 2 year period. Bronchospasm was detected clinically by auscultation and was confirmed by measuring peak airway pressure during mechanical ventilation. Blood gases were measured at predetermined time intervals intraoperatively. Categorical variables were analyzed using Fisher’s exact test, while numerical variables within and between groups were compared using repeated measures general linear model. The incidence of bronchospasm was significantly higher in obese compared to non obese patients (P = 0.027). Peak airway pressures and blood gases differed significantly when comparing non obese patients versus obese patients without bronchospasm versus obese patients with bronchospasm. Hypoventilation resulting in gradual increase of arterial PaCO2 was noted in all groups during surgery. The incidence of bronchospasm is higher in obese patients compared to non obese patients undergoing elective laparoscopic surgery. Airway pressures and blood gas values in obese patients are somewhere between values in non obese patients and values in patients with bronchospasm, thereby implying that obesity is associated with a state where bronchial smooth muscles are not fully relaxed. Consideration of increased airway reactivity in obese patients undergoing laparoscopic surgery is important for improved patient care and uneventful anesthetic course.",{"EN":540},"Bronchospasm in obese patients undergoing elective laparoscopic surgery under general anesthesia",{"VOID":542},"10.1186\u002Fs40064-016-2054-3","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-016-2054-3",[545,560,577,589,601,613,628],{"id":546,"sortIndex":245,"researcher":19,"roles":547,"affiliations":548,"properties":557},"eaa60dee-c417-4d48-b1bd-c8ed1f3eead7",[69],[549],{"id":19,"sortIndex":20,"affiliation":550,"properties":19},{"id":551,"createTime":552,"updateTime":552,"relativeEntities":553,"slug":19,"properties":554,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"7494960e-a3c8-4db3-a576-a30a17088bad","2023-12-25T21:57:23.349+00:00",[],{"title":555},{"VI":556},"Department of Anesthesiology, University of Larissa, Larissa, Greece",{"title":558},{"VI":559},"Elias Mantoudis",{"id":561,"sortIndex":67,"researcher":19,"roles":562,"affiliations":563,"properties":574},"4328ef0a-ce78-4af7-88d8-ab8d927ebc46",[69],[564],{"id":19,"sortIndex":20,"affiliation":565,"properties":19},{"id":566,"createTime":567,"updateTime":568,"relativeEntities":569,"slug":570,"properties":571,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"3ecf1623-38c9-452b-a74a-602e229e7946","2024-01-22T08:47:36.210+00:00","2024-09-29T10:25:21.068+00:00",[],"Department-of-Anesthesiology-Washington-University-School-of-Medicine-St-Louis-USA",{"title":572},{"VI":573},"Department of Anesthesiology, Washington University School of Medicine, St. Louis, USA",{"title":575},{"VI":576},"Menelaos Karanikolas",{"id":578,"sortIndex":116,"researcher":19,"roles":579,"affiliations":580,"properties":586},"95184cb2-697d-4cde-a5ea-5d83d55352e4",[69],[581],{"id":19,"sortIndex":20,"affiliation":582,"properties":19},{"id":551,"createTime":552,"updateTime":552,"relativeEntities":583,"slug":19,"properties":584,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":585},{"VI":556},{"title":587},{"VI":588},"Hronis Ieropoulos",{"id":590,"sortIndex":20,"researcher":19,"roles":591,"affiliations":592,"properties":598},"f6f0729d-4ace-4dc1-b854-40244ff6da79",[69],[593],{"id":19,"sortIndex":20,"affiliation":594,"properties":19},{"id":551,"createTime":552,"updateTime":552,"relativeEntities":595,"slug":19,"properties":596,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":597},{"VI":556},{"title":599},{"VI":600},"Vassilios Tassoudis",{"id":602,"sortIndex":100,"researcher":19,"roles":603,"affiliations":604,"properties":610},"090ec415-70b1-4e22-8d38-3f09f9281cf2",[69],[605],{"id":19,"sortIndex":20,"affiliation":606,"properties":19},{"id":551,"createTime":552,"updateTime":552,"relativeEntities":607,"slug":19,"properties":608,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":609},{"VI":556},{"title":611},{"VI":612},"George Vretzakis",{"id":614,"sortIndex":129,"researcher":19,"roles":615,"affiliations":616,"properties":625},"c1fc2364-ad3f-40f8-a190-2130038dd97a",[69],[617],{"id":19,"sortIndex":20,"affiliation":618,"properties":19},{"id":619,"createTime":620,"updateTime":620,"relativeEntities":621,"slug":19,"properties":622,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"64069f62-21b0-4669-a826-d3bb0dcb32db","2024-01-30T05:15:07.375+00:00",[],{"title":623},{"VI":624},"Intensive Care Unit, University Hospital of Larissa, Larissa, Greece",{"title":626},{"VI":627},"Aik Bouzia",{"id":629,"sortIndex":319,"researcher":19,"roles":630,"affiliations":631,"properties":637},"8cc8e172-a830-4e4e-b423-65edd756a0a1",[69],[632],{"id":19,"sortIndex":20,"affiliation":633,"properties":19},{"id":551,"createTime":552,"updateTime":552,"relativeEntities":634,"slug":19,"properties":635,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":636},{"VI":556},{"title":638},{"VI":639},"Argyro Petsiti",{"url":543,"publisher":641,"properties":656},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":642,"slug":10,"properties":643,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":647,"manageAffiliations":648,"indexDatabases":649,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":644,"title":645,"url":646},{"VOID":13},{"EN":10},{"VOID":16},[],[],[650],{"id":25,"indexDatabase":651,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":652,"label":653,"description":654,"key":35,"publicationTags":655,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":657,"pages":658},{"VOID":298},{"VOID":659},"1-7","2016-04-12",{"id":662,"createTime":663,"updateTime":663,"relativeEntities":664,"slug":19,"properties":665,"entityType":60,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":674,"fullTextUrl":19,"authors":675,"publicationType":140,"publisherRelationship":718,"citationCount":19,"citationInfo":19,"publishDate":738,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"ea2192a6-4950-4a1a-b56a-0ed96f2d0c3a","2024-01-07T23:56:40.969+00:00",[],{"references":666,"abstract":668,"title":670,"doi":672},{"VOID":667},"Halburd RG, Korhonen RJ (2006) Nevanlinna theory for the difference operator. Ann Acad Sci Fenn Math 31:463–478\nJank G, Volkmann L (1985) Meromorphe funktionen und differentialgleichungen. Birkhäuser, Basel-Boston\nLiu K (2009) Meromorphic functions sharing a set with applications to difference equations. J Math Anal Appl 359:384–393\nLiu K, Cao TB (2013) Entire solutions of fermat type \\(q\\)-difference differential equations. Electron J Differ Equ 2013(59):1–10\nLiu K, Cao TB, Cao HZ (2012) Entire solutions of Fermat type differential-difference equations. Arch Math 99:147–155\nLiu K, Yang LZ (2013) On entire solutions of some differential-difference equations. Comput Methods Funct Theory 13:433–447\nLü F, Xu JF (2008) Sharing set and normal families of entire functions and their derivatives. Houst J Math 34(4):1213–1223\nPeng CW, Chen ZX (2013) On a conjecture concerning some nonlinear difference equations. Bull Malays Math Sci Soc 36:221–227\nTang JF, Liao LW (2007) The transcendental meromorphic solutions of a certain type of nonlinear differential ential equations. J Math Anal Appl 334:517–527\nXu N, Cao TB, Liu K (2015) Entire solutions for nonlinear differential-difference equations. Electron J Differ Equ 22:1–8\nYang CC, Laine I (2010) On analogies between nonlinear difference and differential equations. Proc Jpn Acad Ser A 86:10–14\nYi HX, Yang CC (2003) Uniqueness theory of meromorphic functions. Kluwer, New York\nZhang J, Liao LW (2011) On entire solutions of a certain type of nonlinear differential and difference equations. Taiwan J Math 15:2145–2157",{"EN":669},"In this paper, we describe the properties of entire solutions of a nonlinear differential-difference equation and a Fermat type equation, and improve several previous theorems greatly. In addition, we also deduce a uniqueness result for an entire function f(z) that shares a set with its shift \n                  \n                    \n                  \n                  $$f(z+c)$$\n                  \n                    \n                  \n                , which is a generalization of a result of Liu.",{"EN":671},"Entire solutions of nonlinear differential-difference equations",{"VOID":673},"10.1186\u002Fs40064-016-2255-9","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-016-2255-9",[676,691,706],{"id":677,"sortIndex":20,"researcher":19,"roles":678,"affiliations":679,"properties":688},"6b421554-9777-49a5-ab61-a654770889b8",[69],[680],{"id":19,"sortIndex":20,"affiliation":681,"properties":19},{"id":682,"createTime":683,"updateTime":683,"relativeEntities":684,"slug":19,"properties":685,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"62b4b2f1-79b6-4012-8059-6bb916267655","2023-12-07T23:48:42.605+00:00",[],{"title":686},{"VI":687},"College of Science, China University of Petroleum, Qingdao, People’s Republic of China",{"title":689},{"VI":690},"Cuiping Li",{"id":692,"sortIndex":67,"researcher":19,"roles":693,"affiliations":694,"properties":703},"7f5a3c85-4306-4d3e-a5a7-f7b5a2ba82b8",[69],[695],{"id":19,"sortIndex":20,"affiliation":696,"properties":19},{"id":697,"createTime":698,"updateTime":698,"relativeEntities":699,"slug":19,"properties":700,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"4e38ebb4-75ac-427b-8290-94405d51df78","2024-01-25T02:52:07.946+00:00",[],{"title":701},{"VI":702},"Department of Mathematics, Wuyi University, Jiangmen, People’s Republic of China",{"title":704},{"VI":705},"Junfeng Xu",{"id":707,"sortIndex":116,"researcher":19,"roles":708,"affiliations":709,"properties":715},"a0f8b9b2-f85a-4d26-bb22-8f7eba601644",[69],[710],{"id":19,"sortIndex":20,"affiliation":711,"properties":19},{"id":682,"createTime":683,"updateTime":683,"relativeEntities":712,"slug":19,"properties":713,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":714},{"VI":687},{"title":716},{"VI":717},"Feng Lü",{"url":674,"publisher":719,"properties":734},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":720,"slug":10,"properties":721,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":725,"manageAffiliations":726,"indexDatabases":727,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":722,"title":723,"url":724},{"VOID":13},{"EN":10},{"VOID":16},[],[],[728],{"id":25,"indexDatabase":729,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":730,"label":731,"description":732,"key":35,"publicationTags":733,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":735,"pages":736},{"VOID":298},{"VOID":737},"1-8","2016-05-12",{"id":740,"createTime":741,"updateTime":742,"relativeEntities":743,"slug":744,"properties":745,"entityType":60,"verifyStatus":61,"verifyTime":742,"verifyNote":62,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":754,"fullTextUrl":19,"authors":755,"publicationType":140,"publisherRelationship":797,"citationCount":19,"citationInfo":19,"publishDate":818,"publishYear":819,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"4c3e4a1c-ced6-4f23-84a3-a3139b25cf24","2024-01-14T02:27:25.017+00:00","2024-12-07T23:55:58.311+00:00",[],"Girls-Just-Wanna-Have-Fun-a-process-evaluation-of-a-female-youth-driven-physical-activity-based-life-skills-program",{"references":746,"abstract":748,"title":750,"doi":752},{"VOID":747},"Armour K, Sandford R, Duncombe R: Positive youth development and physical activity\u002Fsport interventions: mechanisms leading to sustained impact. Phys Educ Sport Pedagog 2013, 18(3):256-281. 10.1080\u002F17408989.2012.666791\nBoys and Girls Club of America: Smart Girls. 2013. . Accessed March 18 2014 http:\u002F\u002Fwww.bgca.org\u002Fwhatwedo\u002FHealthLifeSkills\u002FPages\u002FSMARTGirls.aspx\nBraun V, Clarke V: Using thematic analysis in psychology. Qual Res Psychol 2006, 3(2):77-101. 10.1191\u002F1478088706qp063oa\nCanada Active Healthy Kids: Don’t let this be the most physical activity our kids get after school. The active healthy kids Canada 2011 report card on physical activity for children and youth. Active Healthy Kids Canada, Toronto; 2011.\nCatalano RF, Berglund ML, Ryan JA, Lonczak HS, Hawkins JD: Positive youth development in the United States: research findings on evaluations of positive youth development programs. Prevention Treatment 2002, 5(1):15a.\nCoakley J: Youth sports: What counts as “Positive Development?”. J Sport Soc Issues 2011, 35(3):306-324. 10.1177\u002F0193723511417311\nCooky C: “Girls just aren’t interested”: The social construction of interest in girls’ sport. Sociol Perspect 2009, 52: 259-283. doi:10.1525\u002Fsop.2009.52.2.259 10.1525\u002Fsop.2009.52.2.259\nCreswell JW: Research design: Qualitative, quantitative, and mixed methods approaches. CA Sage Publications, Thousand Oaks; 2013.\nDamon W: What is positive youth development? Ann Am Acad Polit Soc Sci 2004, 59(13):13-24.\nDanish SJ: Going for the goal: a life skills program for adolescents. Issues in Childrens and Families Lives 1997, 6: 291-312.\nDanish SJ, Forneris T, Hodge K, Heke I: Enhancing youth development through sport. World Leisure J 2004, 46(3):38-49. 10.1080\u002F04419057.2004.9674365\nDeBate RD, Pettee Gabriel K, Zwald M, Huberty J, Zhang Y: Changes in psychosocial factors and physical activity frequency among third- to eighth-grade girls who participated in a developmentally focused youth sport program: a preliminary study. J Sch Health 2009, 79(10):474-484. doi:10.1111\u002Fj.1746-1561.2009.00437.x 10.1111\u002Fj.1746-1561.2009.00437.x\nDenner J, Meyer B, Bean S: Young Women’s Leadership Alliance: youth–adult partnerships in an all‒female after‒school program. J Community Psychol 2005, 33(1):87-100. 10.1002\u002Fjcop.20036\nDobbins M, De Corby K, Robeson P, Husson H, Tirilis D: School-based physical activity programs for promoting physical activity and fitness in children and adolescents aged 6–18. Cochrane Database Syst Rev 2009, 1: CD007651.\nDurlak JA, DuPre EP: Implementation matters: a review of research on the influence of implementation on program outcomes and the factors affecting implementation. Am J Community Psychol 2008, 41(3–4):327-350.\nEccles JS, Barber BL, Stone M, Hunt J: Extracurricular activities and adolescent development. J Soc Issues 2003, 59(4):865-889. 10.1046\u002Fj.0022-4537.2003.00095.x\nFinlay L: Engaging phenomenological analysis. Qual Res Psychol 2014, 11(2):121-141.\nForneris T, Bean CN, Snowden M, Fortier M: Using youth-driven programs to encourage physical activity in adolescent girls: A preliminary study. PHEnex J 2013, 4(3):1-15.\nFutris TG, Sutton TE, Richardson EW: An evaluation of the Relationship Smarts Plus program on adolescents in Georgia. J Hum Sci Extension 2013, 1(2):1-15.\nGirls Incorporated: Girls Inc. Sporting Chance. 2013. . Accessed 28 December 2013 http:\u002F\u002Fgirlsincyork.org\u002Fprograms\u002Fgirls-incorporated-sporting-chance%C2%AE\nGould D, Carson S: Life skills development through sport: current status and future directions. Int Rev Sport Exerc Psychol 2008, 1(1):58-78. 10.1080\u002F17509840701834573\nHeath S, Brooks R, Cleaver E, Ireland E: Researching young people’s lives. Sage, Thousand Oaks; 2009.\nHellison DR: Teaching responsibility through physical activity. Human Kinetics, Champaign; 1995.\nHellison DR: Teaching personal and social responsibility through physical activity. Human Kinetics, Champaign; 2011.\nHellison D, Walsh D: Responsibility-based youth programs evaluation: investigating the investigations. Quest 2002, 54(4):292-307. 10.1080\u002F00336297.2002.10491780\nHellison D, Martinek T, Walsh D, Holt N: Sport and responsible leadership among youth. Positive youth development through sport 2008, 49-60.\nHirsch BJ: Structured Programs: The Implementation of Smart Girls. Teachers College Press, New York; 2005.\nHodge K, Danish S, Martin J: Developing a conceptual framework for life skills interventions. Couns Psychol 2013, 41(8):1125-1152. 10.1177\u002F0011000012462073\nHolt NL (Ed): Positive youth development through sport. Routledge, New York; 2008.\nHolt NL, Jones MI: Future directions for positive youth development and sport research. In Positive youth development through sport. New York: Routledge; 2008.\nKelly P, Matthews A, Foster C: Young and physically active: a blueprint for making physical activity appealing for youth. World Health Organization, Geneva, Switzerland; 2012. Retrieved from, http:\u002F\u002Fwww.euro.who.int\u002F__data\u002Fassets\u002Fpdf_file\u002F0005\u002F175325\u002Fe96697.pdf\nLinnan L, Steckler A: Process evaluation for public health interventions and research. Jossey-Bass, San Francisco; 2002.\nMarkowitz E: Exploring self-esteem in a girls’ sports program: Competencies and connections create change. Afterschool Matters. National Institute of Out-of-School Time, Wellesley Centers for Women, Wellesley College; 2012.\nMartin JJ, Waldron JJ, McCabe A, Choi YS: The impact of “Girls on the Run” on self-concept and fat attitudes. J Clin Sport Psychol 2009, 3(2):127-138.\nMartinek T, Schilling T, Johnson D: Transferring personal and social responsibility of underserved youth to the classroom. Urban Rev 2001, 33(1):29-45. 10.1023\u002FA:1010332812171\nMartinek T, Schilling T, Hellison D: The development of compassionate and caring leadership among adolescents. Phys Educ Sport Pedagog 2006, 11(2):141-157. 10.1080\u002F17408980600708346\nMaxwell JA: Qualitative research design: An interactive approach. Sage, Thousand Oaks; 2005.\nNakkash RT, Alaouie H, Haddad P, El Hajj T, Salem H, Mahfoud Z, Afifi RA: Process evaluation of a community-based mental health promotion intervention for refugee children. Health Educ Res 2012, 27(4):595-607. 10.1093\u002Fher\u002Fcyr062\nOzer EJ, Cantor JP, Cruz GW, Fox B, Hubbard E, Moret L: The diffusion of youth-led participatory research in urban schools: the role of the prevention support system in implementation and sustainability. Am J Community Psychol 2008, 41(3–4):278-289.\nPeters DH, Tran NT, Adam T: Implementation research in health: a practical guide. World Health Organization, Geneva, Switzerland; 2013.\nPetitpas AJ, Cornelius AE, Van Raalte JL, Jones T: A framework for planning youth sport programs that foster psychosocial development. Sport Psychol 2005, 19(1):63-80.\nPollio HR, Henley TB, Thompson CJ: The phenomenology of everyday life. Cambridge University Press, New York; 1997.\nRauscher L, Kauer K, Wilson BDM: Organizational and interactional influences on preadolescent girls’ body image in Los Angeles. Gend Soc 2013, 27(2):208-230. doI:10.1177\u002F0891243212472054 10.1177\u002F0891243212472054\nSalmon J, Booth ML, Phongsavan P, Murphy N, Timperio A: Promoting physical activity participation among children and adolescents. Epidemiol Rev 2007, 29(1):144-159. 10.1093\u002Fepirev\u002Fmxm010\nSaunders RP, Evans MH, Joshi P: Developing a process-evaluation plan for assessing health promotion program implementation: a how-to guide. Health Promot Pract 2005, 6(2):134-147. 10.1177\u002F1524839904273387\nShek DT, Sun RC: Process evaluation of a positive youth development course in a university setting in Hong Kong. Int J Disabil Hum Dev 2012, 11(3):235-241.\nStone EJ, McKenzie TL, Welk GJ, Booth ML: Effects of physical activity interventions in youth: review and synthesis. Am J Prev Med 1998, 15(4):298-315. 10.1016\u002FS0749-3797(98)00082-8\nTheokas C, Almerigi JB, Lerner RM, Dowling EM, Benson PL, Scales PC, von Eye A: Conceptualizing and modeling individual and ecological asset components of thriving in early adolescence. J Early Adolesc 2005, 25(1):113-143. 10.1177\u002F0272431604272460\nThomas H, Ciliska D, Micucci S, Wilson-Abra J, Dobbins M: Effectiveness of physical activity enhancement and obesity prevention programs in children and youth. Effective Public Health Practice Project (EPHPP), Hamilton, ON; 2004.\nWaldron JJ: Influence of involvement in the girls on track program on early adolescent girls’ self-perceptions. Res Q Exerc Sport 2007, 78(5):520-530. 10.1080\u002F02701367.2007.10599451\nWalsh D: Strangers in a strange land: Using an activity course to teach an alternative curriculum model. J Phys Edu, Rec &Dance 2008, 79(2):40-44.\nWalsh DS, Ozaeta J, Wright PM: Transference of responsibility model goals to the school environment: Exploring the impact of a coaching club program. Phys Educ Sport Pedagog 2010, 15(1):15-28. 10.1080\u002F17408980802401252\nWard S, Parker M: The voice of youth: atmosphere in positive youth development program. Phys Educ Sport Pedagog 2013, 18(5):534-548. 10.1080\u002F17408989.2012.726974\nWeiss MR, Wiese-Bjornstal DM: Promoting positive youth development through physical activity. President's Council on Physical Fitness and Sports Research Digest 2009, 3(10):1-8.\nWhitley MA, Forneris T, Barker B: The reality of evaluating community-based sport and physical activity programs to enhance the development of underserved youth: Challenges and potential strategies. Quest 2014, 66(2):218-232. doi:10.1080\u002F00336297.2013.872043 10.1080\u002F00336297.2013.872043\nWindsor RA, Baranowski T, Clark N, Cutter G: Evaluation of Health Promotion and Education Programs. Mayfield, Palo Alto, CA; 1984.\nWright PM, Stockton M, Hays NL: The personal-social responsibility model: Exploring a novel approach to promoting gender equity and increasing relevance for adolescent females in physical education. In Progress in Exercise and Women’s Health Research. Edited by: Coulter J. Hauppauage, NY: Nova Science Publishers Inc; 2008:159-175.\nWright EM, Whitley MA, Sabolboro G: Conducting a TPSR program for an undeserved girls’ summer camp. Agora PE Sport 2012, 14(1):5-24.\nYin RK: Case study research: Design and methods. Sage, Thousand Oaks, CA; 2009.\nYoshida SC, Craypo L, Samuels SE: Engaging youth in improving their food and physical activity environments. J Adolescent Health 2011, 48(6):641-643. 10.1016\u002Fj.jadohealth.2010.09.007",{"EN":749},"Integrating a positive youth development framework into physical activity programming has become popular as it is believed that this integration can create the development of both physical and psychosocial skills. However, there has been a lack of intervention fidelity research within the field of positive youth development. The Girls Just Wanna Have Fun program was designed in response to increased calls for physical activity programs for female youth and is a theoretically-grounded physical activity-based life skills program that aims to empower female youth. The purpose of this paper was to provide a detailed description of the program and a process evaluation of the first year of program implementation. From interviews with youth and leaders, as well as documentation from the leaders’ weekly online log of each implemented session, themes emerged regarding the successes. Findings from this study indicated that program goals were attained and it appears that the program was implemented, for the most part, as designed. The themes related to successes included using activities to facilitate relational time, providing intentional opportunities for leadership, having communicative program leaders who supported one another, and engaging youth in different types of physical activity. The themes related to challenges included difficulties with facility and transportation, some activities being too much like schoolwork, and social distractions and cliques. Included in the paper is a discussion of practical implications and recommendations for community programmers, as well as future directions for the program. Overall, this process evaluation represents an important step in responding to calls for increased evaluation in community-based programs and aids in understanding the process in which positive youth development programs can be effectively implemented.",{"EN":751},"Girls Just Wanna Have Fun: a process evaluation of a female youth-driven physical activity-based life skills program",{"VOID":753},"10.1186\u002F2193-1801-3-401","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002F2193-1801-3-401",[756,773,785],{"id":757,"sortIndex":20,"researcher":19,"roles":758,"affiliations":759,"properties":770},"be5e02a9-56f4-4b64-8dfd-a64b62294a8c",[69],[760],{"id":19,"sortIndex":20,"affiliation":761,"properties":19},{"id":762,"createTime":763,"updateTime":764,"relativeEntities":765,"slug":766,"properties":767,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"6386c9ac-fcb6-49d6-9a7c-0a53bc8a2656","2023-11-26T18:13:53.926+00:00","2024-09-24T16:48:43.154+00:00",[],"School-of-Human-Kinetics-University-of-Ottawa-Ottawa-Canada",{"title":768},{"VI":769},"School of Human Kinetics, University of Ottawa, Ottawa, Canada",{"title":771},{"VI":772},"Corliss N Bean",{"id":774,"sortIndex":67,"researcher":19,"roles":775,"affiliations":776,"properties":782},"e89eb44f-fc98-4e35-b7c0-46e341c64f17",[69],[777],{"id":19,"sortIndex":20,"affiliation":778,"properties":19},{"id":762,"createTime":763,"updateTime":764,"relativeEntities":779,"slug":766,"properties":780,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":781},{"VI":769},{"title":783},{"VI":784},"Tanya Halsall",{"id":786,"sortIndex":116,"researcher":19,"roles":787,"affiliations":788,"properties":794},"5bd112bc-019a-455c-8783-5328e98f7183",[69],[789],{"id":19,"sortIndex":20,"affiliation":790,"properties":19},{"id":762,"createTime":763,"updateTime":764,"relativeEntities":791,"slug":766,"properties":792,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":793},{"VI":769},{"title":795},{"VI":796},"Tanya Forneris",{"url":754,"publisher":798,"properties":813},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":799,"slug":10,"properties":800,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":804,"manageAffiliations":805,"indexDatabases":806,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":801,"title":802,"url":803},{"VOID":13},{"EN":10},{"VOID":16},[],[],[807],{"id":25,"indexDatabase":808,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":809,"label":810,"description":811,"key":35,"publicationTags":812,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":814,"pages":816},{"VOID":815},"3",{"VOID":817},"1-15","2014-08-03",2014,{"id":821,"createTime":822,"updateTime":822,"relativeEntities":823,"slug":19,"properties":824,"entityType":60,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":833,"fullTextUrl":19,"authors":834,"publicationType":140,"publisherRelationship":1004,"citationCount":19,"citationInfo":19,"publishDate":1024,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"41b551cb-3d27-4647-b7a0-a53aa2518978","2023-12-12T23:55:06.359+00:00",[],{"references":825,"abstract":827,"title":829,"doi":831},{"VOID":826},"Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon MS (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR\u002FHER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 24(18S):2074\nArpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29:217–233\nBachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero J-M, Freyer G et al (2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724\nBaselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529\nChu D, Lu J (2008) Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol 1:16\nCiardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174\nCristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP et al (2010) Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 16:1904–1914\nDowsett M (1999) Drug and hormone interactions of aromatase inhibitors. Endocr Relat Cancer 6:181–185\nEskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al (2008) A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80–85\nFinn RS, Press M, Dering J, Florance A, Platek G, Arbushites M et al (2009) Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. ASCO Meeting Abstracts 27(15S):1018\nFrankel C, Palmieri FM (2010) Lapatinib side-effect management. Clin J Oncol Nurs 14:223–233\nHuober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C et al (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer—Results of the eLEcTRA trial. Breast 21:27–33\nHurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666\nHurvitz SA, Pietras RJ (2008) Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 113:2385–2397\nJohnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546\nKaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537\nKlapper LN, Kirschbaum MH, Sela M, Yarden Y (2000) Biochemical and clinical implications of the ErbB\u002FHER signaling network of growth factor receptors. Adv Cancer Res 77:25–79\nLewis N, Marshall J, Amelsberg A, Cohen RB, Stopfer P, Hwang J et al (2006) A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR\u002FHER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumours. J Clin Oncol 24(18S):3091\nLi D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR et al (2008) BIBW2992, an irreversible EGFR\u002FHER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4211–4702\nLin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D et al (2012) A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 133:1057–1065\nMarcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N et al (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102:43–49\nMayer I, Ganja N, Shyr Y, Muldowney N, Arteaga C (2006) A phase II trial of letrozole plus erlotinib in post-menopausal women with hormone-sensitive metastatic breast cancer: preliminary results of toxicities and correlative studies. Breast Cancer Res Treat 100(abstr 4052)\nMita M, de Bono JS, Mita A et al (2005) A phase II and biologic correlative study investigating anastrozole in combination with gefitinib in post menopausal patients with estrogen receptor positive metastatic breast carcinoma who have previously failed hormonal therapy. Breast Cancer Res Treat 94(Suppl 1; abstr 1117)\nMitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128\nMok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957\nMouridsen HT, Rose C, Brodie AH, Smith IE (2003) Challenges in the endocrine management of breast cancer. Breast 12(Suppl 2):S2–S19\nNicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9–S15\nOsborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618\nOsborne CK, Shou J, Massarweh S, Schiff R (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s–870s\nOsborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C et al (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17:1147–1159\nPfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C et al (2001) Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 22:191–197\nRosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246\nSchiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S–336S\nSchuler MH, Uttenreuther-Fischer MM, Piccart-Gebhart MJ, Harbeck N, on behalf of the study group and trial team (2010) BIBW 2992, a novel irreversible EGFR\u002FHER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. J Clin Oncol 28(Suppl):15s (abstr 1065)\nSchwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S (2010) Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 15:122–129\nSmith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S et al (2007) A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25:3816–3822\nTherasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216\nUllrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212\nYap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H et al (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965–3972",{"EN":828},"Phase II, open-label study assessing the efficacy and safety of the ErbB family blocker afatinib combined with letrozole in estrogen receptor-positive metastatic breast cancer (MBC) patients who had progressed on letrozole monotherapy. Adult females (N = 28) received oral afatinib (50 [n = 7], 40 [n = 13] or 30 [n = 8] mg\u002Fday) plus letrozole 2.5 mg\u002Fday in 28-day cycles until disease progression. Primary endpoint was the progression-free rate at or after 16 weeks of afatinib. At 16 weeks, four patients remained on afatinib without progression; two of these were HER2 negative. Fifteen (54 %) patients had a best response of stable disease according to Response Evaluation Criteria in Solid Tumors. Median progression-free survival was 60, 107 and 79 days with 50, 40 and 30 mg\u002Fday afatinib, respectively. Diarrhea, asthenia, rash, mucosal inflammation and nausea were the most frequent adverse events. In this small, exploratory study, afatinib combined with letrozole was able to induce disease stabilization in 54 % of hormone-refractory MBC patients previously progressing on letrozole. Clinical trial registration: NCT00708214",{"EN":830},"A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole",{"VOID":832},"10.1186\u002Fs40064-015-1601-7","http:\u002F\u002Fwww.springerplus.com\u002Fcontent\u002F5\u002F1\u002F45",[835,852,867,882,899,915,927,952,977,992],{"id":836,"sortIndex":372,"researcher":19,"roles":837,"affiliations":838,"properties":849},"7efe76e8-29d0-4732-ae09-449df33d9d9f",[69],[839],{"id":19,"sortIndex":20,"affiliation":840,"properties":19},{"id":841,"createTime":842,"updateTime":843,"relativeEntities":844,"slug":845,"properties":846,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"5e101ce3-b83f-4511-ab5f-dd5fe0ded678","2024-04-16T22:33:42.754+00:00","2024-09-22T17:27:19.876+00:00",[],"H%C3%B4pital-Saint-Louis-Paris-France",{"title":847},{"EN":848},"Hôpital Saint Louis, Paris, France",{"title":850},{"VI":851},"Guilhem Bousquet",{"id":853,"sortIndex":67,"researcher":19,"roles":854,"affiliations":855,"properties":864},"9f40f846-4ecd-41c4-9e03-51a4f2298aa8",[69],[856],{"id":19,"sortIndex":20,"affiliation":857,"properties":19},{"id":858,"createTime":859,"updateTime":859,"relativeEntities":860,"slug":19,"properties":861,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"2254e68e-91fd-4a09-a87a-99f2e1bfc5e3","2024-01-09T03:52:10.380+00:00",[],{"title":862},{"VI":863},"Centre Antoine-Lacassagne, Nice, France",{"title":865},{"VI":866},"Jean-Marc Ferrero",{"id":868,"sortIndex":319,"researcher":19,"roles":869,"affiliations":870,"properties":879},"1ec910e9-748a-40fb-8f38-8e3505700aa3",[69],[871],{"id":19,"sortIndex":20,"affiliation":872,"properties":19},{"id":873,"createTime":874,"updateTime":874,"relativeEntities":875,"slug":19,"properties":876,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"5cedac09-9a4b-44e8-bb09-dd8550a743d7","2024-01-03T08:18:33.412+00:00",[],{"title":877},{"VI":878},"Boehringer Ingelheim Ltd., Bracknell, UK",{"title":880},{"VI":881},"Katy Pelling",{"id":883,"sortIndex":884,"researcher":19,"roles":885,"affiliations":886,"properties":896},"7d7e5160-2915-4558-87d1-eee13780ee48",9,[69],[887],{"id":19,"sortIndex":20,"affiliation":888,"properties":19},{"id":889,"createTime":890,"updateTime":891,"relativeEntities":892,"slug":845,"properties":893,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"b23239a7-2f75-4557-95d6-8ae966adf8b0","2023-12-28T14:56:20.923+00:00","2025-02-04T07:23:46.291+00:00",[],{"title":894},{"VI":895},"Hôpital Saint-Louis, Paris, France",{"title":897},{"VI":898},"Jean-Louis Misset",{"id":900,"sortIndex":245,"researcher":19,"roles":901,"affiliations":902,"properties":912},"bf742cd2-966f-422e-b64b-71a7e2040e2c",[69],[903],{"id":19,"sortIndex":20,"affiliation":904,"properties":19},{"id":905,"createTime":906,"updateTime":906,"relativeEntities":907,"slug":908,"properties":909,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"d0f9de3c-7969-482a-8541-543d3fa07f30","2024-04-17T07:02:14.005+00:00",[],"Boehringer-Ingelheim-Pharma-GmbH-and-Co-KG-Biberach-Germany",{"title":910},{"EN":911},"Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany",{"title":913},{"VI":914},"Martina Uttenreuther-Fischer",{"id":916,"sortIndex":359,"researcher":19,"roles":917,"affiliations":918,"properties":924},"ce023a4d-1a37-40e8-babe-fee721a01a61",[69],[919],{"id":19,"sortIndex":20,"affiliation":920,"properties":19},{"id":905,"createTime":906,"updateTime":906,"relativeEntities":921,"slug":908,"properties":922,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":923},{"EN":911},{"title":925},{"VI":926},"Sven Wind",{"id":928,"sortIndex":100,"researcher":19,"roles":929,"affiliations":930,"properties":949},"0fe19ca2-4751-4a94-b012-4d3682acb378",[69],[931,939],{"id":19,"sortIndex":20,"affiliation":932,"properties":19},{"id":933,"createTime":934,"updateTime":934,"relativeEntities":935,"slug":19,"properties":936,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"f9b34034-9f6b-418b-95e4-c41c5ce30c82","2023-12-12T23:54:53.593+00:00",[],{"title":937},{"VI":938},"APHP, HUEP-Tenon Hospital, Paris, France",{"id":940,"sortIndex":116,"affiliation":941,"properties":948},"a84f6d88-e418-40cb-a6a3-664ba7fec4d0",{"id":942,"createTime":943,"updateTime":943,"relativeEntities":944,"slug":19,"properties":945,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"37a084d0-b80c-407a-b9c5-0cf9a5385987","2023-12-12T23:54:53.599+00:00",[],{"title":946},{"VI":947},"Institut Universitaire de Cancérologie, UPMC, Paris, France",{},{"title":950},{"VI":951},"Joseph Gligorov",{"id":953,"sortIndex":116,"researcher":19,"roles":954,"affiliations":955,"properties":974},"bbb94694-0668-4566-ad6e-e97a226ea09e",[69],[956,964],{"id":19,"sortIndex":20,"affiliation":957,"properties":19},{"id":958,"createTime":959,"updateTime":959,"relativeEntities":960,"slug":19,"properties":961,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"b5021919-90ae-47f4-a6c3-016e0aa3b054","2023-12-12T23:55:06.534+00:00",[],{"title":962},{"VI":963},"Oncologue-Service de Recherche Clinique, Centre François Baclesse, Caen Cedex 05, France",{"id":965,"sortIndex":116,"affiliation":966,"properties":973},"fcf7cdd2-cdc1-4710-b265-3e00f79be2a7",{"id":967,"createTime":968,"updateTime":968,"relativeEntities":969,"slug":19,"properties":970,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"565ce3e2-12e8-43e1-851b-6df8f27b4825","2023-12-12T23:55:06.581+00:00",[],{"title":971},{"VI":972},"Centre Hospitalier Universitaire Côte de Nacre, Caen, France",{},{"title":975},{"VI":976},"Florence Joly",{"id":978,"sortIndex":129,"researcher":19,"roles":979,"affiliations":980,"properties":989},"1354a042-6675-4739-bd94-8a610bf9da2a",[69],[981],{"id":19,"sortIndex":20,"affiliation":982,"properties":19},{"id":983,"createTime":984,"updateTime":984,"relativeEntities":985,"slug":19,"properties":986,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"8360e7f9-219b-44be-b749-79a56c2514ed","2024-02-10T10:12:50.209+00:00",[],{"title":987},{"VI":988},"Boehringer Ingelheim France S.A.S, Reims, France",{"title":990},{"VI":991},"Helene de Mont-Serrat",{"id":993,"sortIndex":20,"researcher":19,"roles":994,"affiliations":995,"properties":1001},"f7dde8e3-0639-4b80-b638-28e6e3e88202",[69],[996],{"id":19,"sortIndex":20,"affiliation":997,"properties":19},{"id":958,"createTime":959,"updateTime":959,"relativeEntities":998,"slug":19,"properties":999,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":1000},{"VI":963},{"title":1002},{"VI":1003},"Katharina Gunzer",{"url":833,"publisher":1005,"properties":1020},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1006,"slug":10,"properties":1007,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":1011,"manageAffiliations":1012,"indexDatabases":1013,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":1008,"title":1009,"url":1010},{"VOID":13},{"EN":10},{"VOID":16},[],[],[1014],{"id":25,"indexDatabase":1015,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":1016,"label":1017,"description":1018,"key":35,"publicationTags":1019,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":1021,"pages":1022},{"VOID":298},{"VOID":1023},"1-12","2016-01-19",{"id":1026,"createTime":1027,"updateTime":1028,"relativeEntities":1029,"slug":1030,"properties":1031,"entityType":60,"verifyStatus":61,"verifyTime":1028,"verifyNote":62,"syncStatus":18,"languages":1046,"translateLanguages":19,"viewCount":20,"primaryUrl":1048,"fullTextUrl":19,"authors":1049,"publicationType":140,"publisherRelationship":1124,"citationCount":359,"citationInfo":1144,"publishDate":1146,"publishYear":819,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":1147,"isForceReanalyzing":164},"dedab3c5-5596-4c73-84a3-a800fb9a0d3f","2024-04-21T06:07:47.105+00:00","2024-12-07T23:54:55.401+00:00",[],"Efficacy-of-Oryza-sativa-husk-and-Quercus-phillyraeoides-extracts-for-the-in-vitro-and-in-vivo-control-of-fungal-rot-disease-of-white-yam-Dioscorea-rotundata-Poir-",{"mag":1032,"keywords":1034,"pmc":1035,"openalex":1037,"abstract":1039,"title":1040,"pm":1042,"doi":1044},{"VOID":1033},"2150781286",{},{"VOID":1036},"4320188",{"VOID":1038},"W2150781286",{},{"EN":1041},"Efficacy of Oryza sativa husk and Quercus phillyraeoides extracts for the in vitro and in vivo control of fungal rot disease of white yam (Dioscorea rotundata Poir)",{"VOID":1043},"25674452",{"VOID":1045},"10.1186\u002F2193-1801-3-711",[1047],"EN","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002F2193-1801-3-711",[1050,1070,1087,1107],{"id":1051,"sortIndex":67,"researcher":19,"roles":1052,"affiliations":1053,"properties":1065},"5c2ed763-cb11-40d8-bcc8-81574bc31200",[],[1054],{"id":1055,"sortIndex":20,"affiliation":1056,"properties":19},"5d840930-233e-4aec-aacf-5e5e291f863d",{"id":1057,"createTime":1058,"updateTime":1059,"relativeEntities":1060,"slug":1061,"properties":1062,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"56a0f279-2690-4f39-a34e-0524a965ae41","2023-12-26T03:16:58.017+00:00","2024-12-23T05:52:37.298+00:00",[],"International-Institute-of-Tropical-Agriculture-IITA-Ibadan-Nigeria",{"title":1063},{"VI":1064},"International Institute of Tropical Agriculture (IITA), Ibadan, Nigeria",{"openalex":1066,"title":1068},{"VOID":1067},"A5073253982",{"EN":1069},"Maria Ayodele",{"id":1071,"sortIndex":20,"researcher":19,"roles":1072,"affiliations":1073,"properties":1080},"758bcd8b-74e7-4073-a7a3-1e779a14eee4",[],[1074],{"id":1075,"sortIndex":20,"affiliation":1076,"properties":19},"bdf2344a-9f05-4682-893e-265be9f9b664",{"id":1057,"createTime":1058,"updateTime":1059,"relativeEntities":1077,"slug":1061,"properties":1078,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":1079},{"VI":1064},{"openalex":1081,"orcid":1083,"title":1085},{"VOID":1082},"A5048919146",{"VOID":1084},"https:\u002F\u002Forcid.org\u002F0000-0001-7980-5159",{"EN":1086},"Victor Ohileobo Dania",{"id":1088,"sortIndex":116,"researcher":19,"roles":1089,"affiliations":1090,"properties":1102},"465a63f5-9dd3-4b4b-96ee-0522d4fb6a4a",[],[1091],{"id":1092,"sortIndex":20,"affiliation":1093,"properties":19},"36ddf7b6-b2ad-409c-bd58-e2f49f9885df",{"id":1094,"createTime":1095,"updateTime":1096,"relativeEntities":1097,"slug":1098,"properties":1099,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"edd8a518-8df1-42c7-89ea-1ecf5c39ed99","2023-12-23T22:06:49.310+00:00","2025-01-03T14:37:00.899+00:00",[],"Department-of-Crop-Protection-and-Environmental-Biology-University-of-Ibadan-Ibadan-Nigeria",{"title":1100},{"VI":1101},"Department of Crop Protection and Environmental Biology, University of Ibadan, Ibadan, Nigeria",{"openalex":1103,"title":1105},{"VOID":1104},"A5021372949",{"EN":1106},"O. O. Fadina",{"id":1108,"sortIndex":100,"researcher":19,"roles":1109,"affiliations":1110,"properties":1117},"6ea39a1b-8f71-462e-b3b0-abfa7f98bd6b",[],[1111],{"id":1112,"sortIndex":20,"affiliation":1113,"properties":19},"23ac76e4-9f32-4b51-8359-9475a8c35d75",{"id":1057,"createTime":1058,"updateTime":1059,"relativeEntities":1114,"slug":1061,"properties":1115,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":1116},{"VI":1064},{"openalex":1118,"orcid":1120,"title":1122},{"VOID":1119},"A5059610152",{"VOID":1121},"https:\u002F\u002Forcid.org\u002F0000-0001-8949-3427",{"EN":1123},"Pardeep Kumar",{"url":19,"publisher":1125,"properties":1140},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1126,"slug":10,"properties":1127,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":1131,"manageAffiliations":1132,"indexDatabases":1133,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":1128,"title":1129,"url":1130},{"VOID":13},{"EN":10},{"VOID":16},[],[],[1134],{"id":25,"indexDatabase":1135,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":1136,"label":1137,"description":1138,"key":35,"publicationTags":1139,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":1141,"issue":1142},{"VOID":815},{"VOID":1143},"1",{"total":359,"publishYear":19,"statisticByYear":1145},{"2020":129,"2022":116,"2023":116,"2024":116},"2014-12-01",[1148,1151,1155,1158,1162,1166,1170,1173,1176,1179,1182,1185,1189,1193,1196,1199,1202,1205,1208,1212,1215,1218,1221,1224,1227,1230,1233,1236,1239,1242],{"id":19,"text":1149,"url":19,"identifiers":1150},"Abiala M: Evaluation of plant extracts and microbial agents in the in vitro control of Mycosphaerella fijiensis. M.Sc Dissertation. University of Ibadan; 2008:95.",{},{"id":19,"text":1152,"url":19,"identifiers":1153},"Aboagyne-Nuamah FSK, Offei EW, Cornelius RD, Bancroft J: Severity of spoilage storage rots of white yam ( Dioscorea rotundata Poir). Ann Appl Biol 2005, 147(2):183-190. 10.1111\u002Fj.1744-7348.2005.00028.x",{"doi":1154},"10.1111\u002Fj.1744-7348.2005.00028.x",{"id":19,"text":1156,"url":19,"identifiers":1157},"Aidoo AK: Identification of yam tuber rot fungi from storage systems at the Kumasi Central Market. A dissertation submitted to Faculty of Agriculture. K.N.U.S.T; 2007:79.",{},{"id":19,"text":1159,"url":19,"identifiers":1160},"Amadioha AC: Fungitoxic effects of some leaf extracts against Rhizopus oryzae causing tuber rot of potato. Arch Phytopathol 2000, 7: 1-9.",{"doi":1161},"10.1080\u002F03235400009383323",{"id":19,"text":1163,"url":19,"identifiers":1164},"Amusa NA, Adegbite AA, Mohammed S, Baiyewu RA: Yam diseases and its management in Nigeria. Afr J Biotechnol 2003, 12: 497-502.",{"doi":1165},"10.5897\u002FAJB2003.000-1099",{"id":19,"text":1167,"url":19,"identifiers":1168},"Arua EO: Yam ceremonies and the values of Ohafia culture. Africa 1981, 51: 694-705. 10.2307\u002F1158833",{"doi":1169},"10.2307\u002F1158833",{"id":19,"text":1171,"url":19,"identifiers":1172},"Babaleye T: Raising the status of the yam, a major food crop in West Africa. ANB-BIA Suppl Issue\u002FEd 2003, 463: 1-3.",{},{"id":19,"text":1174,"url":19,"identifiers":1175},"Barnett HL, Hunter BB: Illustrated Genera of imperfect Fungi. 4th edition. Macmillan Inc, New York; 1998:218.",{},{"id":19,"text":1177,"url":19,"identifiers":1178},"Coursey DG: Yams. Handbook of Tropical Foods. In International Review of Yams. Edited by: Chan HT. New York: Dekker; 1983:555-601.",{},{"id":19,"text":1180,"url":19,"identifiers":1181},"Dania VO: Evaluation of some plant extracts and microbial agents for the control of post-harvest fungal rot of yam (Dioscorea spp.) Ph.D Thesis. University of Ibadan; 2012:219.",{},{"id":19,"text":1183,"url":19,"identifiers":1184},"Dhaliwal GS, Pathlak MD, Vega CR: Effect of plant extracts of rice varieties on insect pests and predator complex of rice. J Crop Sci 1993, 1993(7):51-64.",{},{"id":19,"text":1186,"url":19,"identifiers":1187},"Ejechi BO, Souzey JA: Inhibition of bio-deterioration of yam tuber ( Dioscorea rotundata Poir) in storage with phenolic extracts of Acalypha hispida burm F. leaves. J Stored Prod Res 1999, 35: 127-134. 10.1016\u002FS0022-474X(98)00038-1",{"doi":1188},"10.1016\u002FS0022-474X(98)00038-1",{"id":19,"text":1190,"url":19,"identifiers":1191},"Enikuomehin OA, Ikotun T, Ekpo EJA: Evaluation of ash from some tropical plants of Nigeria for the control of Sclerotium rolfsii Sacc. on wheat ( Triticum aestivum L.). Mycopathol 1998, 142: 81-87. 10.1023\u002FA:1006926817580",{"doi":1192},"10.1023\u002FA:1006926817580",{"id":19,"text":1194,"url":19,"identifiers":1195},"Fuerhake KJ: Effectiveness and selectivity of technical solvents for the extraction of neem seed components with insecticidal activity. In Natural pesticides from the neem tree and other tropical plants. Edited by: Schumutterer H, Ascher KRS, Rembold GTZ. Echborn: Proceedings of second International Neem Conference; 1984:103-114.",{},{"id":19,"text":1197,"url":19,"identifiers":1198},"Ghana Organic Agricultural Network (GOAN): The organic farmer. Quarterly newsletter of GOAN. 1999, 7.",{},{"id":19,"text":1200,"url":19,"identifiers":1201},"Hycenth N: Effects of different plant extracts in the control of yam rot induced by Rhizopus stolonifer on stored yam ( Dioscorea sp.) in Yola, Adamawa state, Nigeria. Agric J 2008, 3(5):382-387.",{},{"id":19,"text":1203,"url":19,"identifiers":1204},"Ikotun T: Post-harvest microbial rot of yam in Nigeria. Fitopathologie Bras 1983, 1983(8):1-7.",{},{"id":19,"text":1206,"url":19,"identifiers":1207},"Ikotun T: Disease of yam tubers. Int J Trop Plant 1989, 7: 1-21.",{},{"id":19,"text":1209,"url":19,"identifiers":1210},"Lale NES, Abdulrahaman TA: Evaluation of neem ( Azadirachta indica A. Juss) seed oil obtained by different methods of neem powder fot the management of Callosobruchus maculatus (F) (Coleoptera: Bruchidae) in stored cowpea. J Stored Prod Res 1998, 35(2):135-143.",{"doi":1211},"10.1016\u002FS0022-474X(98)00039-3",{"id":19,"text":1213,"url":19,"identifiers":1214},"Manjula K, Mwangi M, Bandyopadhyay R: Potentials of some bacteria and fungi as biocontrol agents of cassava and yam under laboratory and green house conditions. Afr Crop Sci Proc 2005, 7: 1395-1400.",{},{"id":19,"text":1216,"url":19,"identifiers":1217},"Noon PA: Storage and market diseases of yams. Trop Sci 1978, 1978: 17-81.",{},{"id":19,"text":1219,"url":19,"identifiers":1220},"Ogaraku AO, Usman HO: Storage rot of some yams ( Dioscorea spp.) in Keffi and Environs, Nasarawa State, Nigeria. Patnsuk J 2008, 4(2):22-27.",{},{"id":19,"text":1222,"url":19,"identifiers":1223},"Okorji EC: Economics of yam production in Southern Nigeria. Beur Trop Landwirsch Vet Me 1992, 30: 77-84.",{},{"id":19,"text":1225,"url":19,"identifiers":1226},"Olugbade TA, Odebiyi CO, Aladesanmi JA: Antibacteria alkaloids in Crinum jagus . Pharmacognosy 1992, 304: 303-307.",{},{"id":19,"text":1228,"url":19,"identifiers":1229},"Peluola CO: Evaluation of botanicals and microbial agents in the control of some pathogens of cowpea. Ph.D dissertation. University of Ibadan; 2005:159.",{},{"id":19,"text":1231,"url":19,"identifiers":1232},"Prakash A, Rao J, C.R.R.I Cuttack: Biodeterioration of paddy seed quality due to insects and mites and its control using botanicals. Annual report of ICAR. Adhoc Scheme (1993–1994). India; 1994:37.",{},{"id":19,"text":1234,"url":19,"identifiers":1235},"Purseglove JW: Tropical Crops. Monocotyledons. Longman, London; 1985:97-117.",{},{"id":19,"text":1237,"url":19,"identifiers":1238},"Sofowora A J Med Herbs. In Medicinal Plants and Traditional Medicines in Africa. Volume 4. Chichester John Wiley & Sons, New York; 1993:97-145.",{},{"id":19,"text":1240,"url":19,"identifiers":1241},"Titteh JP, Saakwa R: Prospects and constraints of yam production in Ghana. 3. In Proceedings of the 9th symposium of the International Society for Tropical root Crops. Edited by: Ofori CG, Halm PC. Ghana: Accra; 1994:20-26.",{},{"id":19,"text":1243,"url":19,"identifiers":1244},"Yoshida T, Hirojuki T, Eiji T, Hiroshi K: Effect of components of pyroligneous acid on several plant pathogenic fungi. Jpn J Crop Sci 2000, 98: 196-197.",{},{"id":1246,"createTime":1247,"updateTime":1248,"relativeEntities":1249,"slug":1250,"properties":1251,"entityType":60,"verifyStatus":61,"verifyTime":1248,"verifyNote":62,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"primaryUrl":1260,"fullTextUrl":19,"authors":1261,"publicationType":140,"publisherRelationship":1351,"citationCount":19,"citationInfo":19,"publishDate":1371,"publishYear":301,"citationAnalyzeStatus":18,"lastCitationAnalyze":19,"indexDatabases":19,"openAccess":19,"references":19,"isForceReanalyzing":164},"856676bf-5745-4767-866f-b66d90314ec4","2024-01-18T22:18:01.147+00:00","2024-12-10T23:54:53.020+00:00",[],"Review-of-evolving-etiologies-implications-and-treatment-strategies-for-the-superior-vena-cava-syndrome",{"references":1252,"abstract":1254,"title":1256,"doi":1258},{"VOID":1253},"Ahmann FR (1984) A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol 2:961–969\nAmpil F, Caldito G, Previgliano C (2012) Palliative radiotherapy for superior vena caval obstruction by lung cancer: a major issue about timing and a minor issue about efficacy. Ann Thorac Med 7:170–171. doi:10.4103\u002F1817-1737.98854\nArmstrong BA, Perez CA, Simpson JR, Hederman MA (1987) Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 13:531–539\nBaker GL, Barnes HJ (1992) Superior vena cava syndrome: etiology, diagnosis, and treatment. Am J Crit Care 1:54–64\nBekelman JE, Hahn SM (2014) Reference pricing with evidence development: a way forward for proton therapy. J Clin Oncol 32:1540–1542. doi:10.1200\u002Fjco.2014.55.6613\nBekelman JE, Asch DA, Tochner Z, Friedberg J, Vaughn DJ, Rash E, Raksowski K, Hahn SM (2014) Principles and reality of proton therapy treatment allocation. Int J Radiat Oncol Biol Phys 89:499–508. doi:10.1016\u002Fj.ijrobp.2014.03.023\nChan RH, Dar AR, Yu E, Stitt LW, Whiston F, Truong P, Vincent MD, Kocha WI (1997) Superior vena cava obstruction in small-cell lung cancer. Int J Radiat Oncol Biol Phys 38:513–520\nCharnsangavej C, Carrasco CH, Wallace S, Wright KC, Ogawa K, Richli W, Gianturco C (1986) Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 161:295–298. doi:10.1148\u002Fradiology.161.2.3763891\nChen JC, Bongard F, Klein SR (1990) A contemporary perspective on superior vena cava syndrome. Am J Surg 160:207–211\nCheng S (2009) Superior vena cava syndrome: a contemporary review of a historic disease. Cardiol Rev 17:16–23\nCheung P, Faria S, Ahmed S, Chabot P, Greenland J, Kurien E, Mohamed I, Wright JR, Hollenhorst H, de Metz C, Campbell H, Vu TT, Karvat A, Wai ES, Ung YC, Goss G, Shepherd FA, O’Brien P, Ding K, O’Callaghan C (2014) Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non-small cell lung cancer: NCIC CTG BR.25. J Natl Cancer Inst. doi:10.1093\u002Fjnci\u002Fdju164\nDavenport D, Ferree C, Blake D, Raben M (1976) Response of superior vena cava syndrome to radiation therapy. Cancer 38:1577–1580. doi:10.1002\u002F1097-0142(197610)38:4\u003C1577:AID-CNCR2820380422>3.0.CO;2-K\nDavenport D, Ferree C, Blake D, Raben M (1978) Radiation therapy in the treatment of superior vena caval obstruction. Cancer 42:2600–2603\nde Jager CP, Rutten MJ, Lips DJ (2013) “Benign” superior vena cava syndrome. Intensive Care Med 39:572–573. doi:10.1007\u002Fs00134-013-2855-6\nDe Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, Spahn M, Mareel M (2014) Radiotherapy for renal-cell carcinoma. Lancet Oncol 15:e170–e177. doi:10.1016\u002Fs1470-2045(13)70569-2\nDe Ruysscher D, Mark Lodge M, Jones B, Brada M, Munro A, Jefferson T, Pijls-Johannesma M (2012) Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol 103:5–7. doi:10.1016\u002Fj.radonc.2012.01.003\nDevita V (1997) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia. ISBN 13: 9780397515738\nDin OS, Harden SV, Hudson E, Mohammed N, Pemberton LS, Lester JF, Biswas D, Magee L, Tufail A, Carruthers R, Sheikh G, Gilligan D, Hatton MQ (2013) Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol 109:8–12. doi:10.1016\u002Fj.radonc.2013.07.014\nEgelmeers A, Goor C, van Meerbeeck J, van den Weyngaert D, Scalliet P (1996) Palliative effectiveness of radiation therapy in the treatment of superior vena cava syndrome. Bull Cancer Radiother 83:153–157\nEren S, Karaman A, Okur A (2006) The superior vena cava syndrome caused by malignant disease. Imaging with multi-detector row CT. Eur J Radiol 59:93–103. doi:10.1016\u002Fj.ejrad.2006.01.003\nFagedet D, Thony F, Timsit JF, Rodiere M, Monnin-Bares V, Ferretti GR, Vesin A, Moro-Sibilot D (2013) Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol 36:140–149. doi:10.1007\u002Fs00270-011-0310-z\nFunakoshi T, Latif A, Galsky MD (2014) Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials. Cancer Treat Rev 40:636–647. doi:10.1016\u002Fj.ctrv.2014.02.004\nGauden SJ (1993) Superior vena cava syndrome induced by bronchogenic carcinoma: is this an oncological emergency? Australas Radiol 37:363–366\nGray BH, Olin JW, Graor RA, Young JR, Bartholomew JR, Ruschhaupt WF (1991) Safety and efficacy of thrombolytic therapy for superior vena cava syndrome. Chest 99:54–59\nGwon DI, Ko GY, Kim JH, Shin JH, Yoon HK, Sung KB (2013) Malignant superior vena cava syndrome: a comparative cohort study of treatment with covered stents versus uncovered stents. Radiology 266:979–987. doi:10.1148\u002Fradiol.12120517\nHamzik J, Chudej J, Dzian A, Sokol J, Kubisz P (2015) Endovascular stenting in malignant obstruction of superior vena cava. Int J Surg Case Rep 13:84–87. doi:10.1016\u002Fj.ijscr.2015.06.017\nHennequin LM, Fade O, Fays JG, Bic JF, Jaafar S, Bertal A, Anthoine D, Bernadac PA (1995) Superior vena cava stent placement: results with the Wallstent endoprosthesis. Radiology 196:353–361. doi:10.1148\u002Fradiology.196.2.7617844\nHohloch K, Bertram N, Trumper L, Beissbarth T, Griesinger F (2014) Superior vena cava syndrome caused by a malignant tumor: a retrospective single-center analysis of 124 cases. J Cancer Res Clin Oncol. doi:10.1007\u002Fs00432-014-1764-6\nHunter W, Johnston W (1757) The history of an aneurysm of the aorta, with some remarks on aneurysms in general. Medical observations and inquiries, vol 1. William Johnston, London\nKhan UA, Shanholtz CB, McCurdy MT (2014) Oncologic mechanical emergencies. Emerg Med Clin N Am 32:495–508. doi:10.1016\u002Fj.emc.2014.04.001\nKim HJ, Kim HS, Chung SH (1993) CT diagnosis of superior vena cava syndrome: importance of collateral vessels. AJR Am J Roentgenol 161:539–542. doi:10.2214\u002Fajr.161.3.8352099\nKishi K, Sonomura T, Mitsuzane K, Nishida N, Yang RJ, Nomura S, Satoh M, Yamada R, Kobayashi H, Juri M et al (1992) Expandable metallic stent therapy for SVC syndrome-effects on local venous pressure, vascular diameter, symptoms, and these correlations. Nihon Igaku Hoshasen Gakkai Zasshi 52:1661–1670\nKishi K, Sonomura T, Mitsuzane K, Nishida N, Yang RJ, Sato M, Yamada R, Shirai S, Kobayashi H (1993) Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations. Radiology 189:531–535. doi:10.1148\u002Fradiology.189.2.8210386\nKoetters KT (2012) Superior vena cava syndrome. J Emerg Nurs 38:135–138x. doi:10.1016\u002Fj.jen.2010.08.019 (quiz 199)\nKomoda S, Komoda T, Knosalla C, Pavel ME, Morawietz L, von Weikersthal LF, Lehmkuhl HB, Hetzer R (2012) A giant neuroendocrine tumor of the thymus gland causing superior vena cava syndrome. Gen Thorac Cardiovasc Surg 60:863–867. doi:10.1007\u002Fs11748-012-0104-5\nKvale PA, Selecky PA, Prakash UBS (2007) Palliative care in lung cancer*: Accp evidence-based clinical practice guidelines (2nd edition). Chest 132:368S–403S. doi:10.1378\u002Fchest.07-1391\nLacombe J, Mange A, Azria D, Solassol J (2013) Identification of predictive biomarkers to radiotherapy outcome through proteomics approaches. Cancer Radiother. 17:62–69. doi:10.1016\u002Fj.canrad.2012.11.003 quiz 70, 72\nLacout A, Marcy PY, Thariat J, Lacombe P, El Hajjam M (2012) Radio-anatomy of the superior vena cava syndrome and therapeutic orientations. Diagn Interv Imaging 93:569–577. doi:10.1016\u002Fj.diii.2012.03.025\nLanciego C, Pangua C, Chacon JI, Velasco J, Boy RC, Viana A, Cerezo S, Garcia LG (2009) Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgenol 193:549–558. doi:10.2214\u002Fajr.08.1904\nLonardi F, Gioga G, Agus G, Coeli M, Campostrini F (2002) Double-flash, large-fraction radiation therapy as palliative treatment of malignant superior vena cava syndrome in the elderly. Support Care Cancer 10:156–160. doi:10.1007\u002Fs00520-001-0313-4\nMaki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100:623–626\nMaleux G, Gillardin P, Fieuws S, Heye S, Vaninbroukx J, Nackaerts K (2013) Large-bore nitinol stents for malignant superior vena cava syndrome: factors influencing outcome. AJR Am J Roentgenol 201:667–674. doi:10.2214\u002Fajr.12.9582\nMarcy P-Y, Magne N, Bentolila F, Drouillard J, Bruneton J-N, Descamps B (2001) Superior vena cava obstruction: is stenting necessary? Support Care Cancer 9:103–107\nMartin M, Baumgartner I, Kolb M, Triller J, Dinkel HP (2002) Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome. Journal Endovasc Ther 9:680–684. doi:10.1583\u002F1545-1550(2002)009\u003C0680:fptawi>2.0.co;2\nMcKenzie JT, McTyre E, Kunaprayoon D, Redmond KP (2013) Stereotactic body radiotherapy for superior vena cava syndrome. Rep Pract Oncol Radiother 18:179–181. doi:10.1016\u002Fj.rpor.2012.12.003\nMineo TC, Ambrogi V, Nofroni I, Pistolese C (1999) Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients. Ann Thorac Surg 68:223–226\nMitin T, Zietman AL (2014) Promise and pitfalls of heavy-particle therapy. J Clin Oncol 32:2855–2863. doi:10.1200\u002Fjco.2014.55.1945\nMose S, Stabik C, Eberlein K, Ramm U, Bottcher HD, Budischewski K (2006) Retrospective analysis of the superior vena cava syndrome in irradiated cancer patients. Anticancer Res 26:4933–4936\nNagata T, Makutani S, Uchida H, Kichikawa K, Maeda M, Yoshioka T, Anai H, Sakaguchi H, Yoshimura H (2007) Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol 30:959–967. doi:10.1007\u002Fs00270-007-9088-4\nNicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF (1997) Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 8:781–788\nNogeire C, Mincer F, Botstein C (1979) Long survival in patients with bronchogenic carcinoma complicated by superior vena caval obstruction. Chest 75:325–329. doi:10.1378\u002Fchest.75.3.325\nOlsen DR, Bruland ØS, Frykholm G, Norderhaug IN (2007) Proton therapy: a systematic review of clinical effectiveness. Radiother Oncol 83:123–132. doi:10.1016\u002Fj.radonc.2007.03.001\nOstler PJ, Clarke DP, Watkinson AF, Gaze MN (1997) Superior vena cava obstruction: a modern management strategy. Clin oncol (R Coll Radiol) 9:83–89\nParish JM, Marschke RF Jr, Dines DE, Lee RE (1981) Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc 56:407–413\nPercarpio B, Gray S (1979) Prolonged survival following the superior vena cava syndrome. Chest J 75:639–640\nPereira JR, Martins SJ, Ikari FK, Nikaedo SM, Gampel O (1999) Neoadjuvant chemotherapy vs. radiotherapy alone for superior vena cava syndrome (SVCS) due to non-small cell lung cancer (NSCLC): preliminary results of randomized phase II trial. Eur J Cancer 35(Supplement 4):S260. doi:10.1016\u002FS0959-8049(99)81452-X\nPerez C, Brady L, Waver D, Freeman C (2007) Perez and Brady’s principles and practice of radiation oncology, 5th edn. Lipincott Williams & Wilkin, Philadelphia. ISBN-13: 9780781763691\nRachapalli V, Boucher LM (2014) Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J. 65:168–176. doi:10.1016\u002Fj.carj.2012.09.003\nRice TW, Rodriguez RM, Light RW (2006a) The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine 85:37–42. doi:10.1097\u002F01.md.0000198474.99876.f0\nRice TW, Rodriguez RM, Barnette R, Light RW (2006b) Prevalence and characteristics of pleural effusions in superior vena cava syndrome. Respirology 11:299–305. doi:10.1111\u002Fj.1440-1843.2006.00841.x\nRizvi AZ, Kalra M, Bjarnason H, Bower TC, Schleck C, Gloviczki P (2008) Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg 47:372–380. doi:10.1016\u002Fj.jvs.2007.09.071\nRobinson C, Stephans K, Reddy C, Djemil T, Videtic G (2009) Stereotactic body radiotherapy (SBRT) for radiographically diagnosed primary lung cancer without histologic confirmation. Int J Radiat Oncol Biol Phys 75:S453–S454. doi:10.1016\u002Fj.ijrobp.2009.07.1037\nRodrigues CI, Njo KH, Karim AB (1993) Hypofractionated radiation therapy in the treatment of superior vena cava syndrome. Lung cancer. 10:221–228\nRosch J, Uchida BT, Hall LD, Antonovic R, Petersen BD, Ivancev K, Barton RE, Keller FS (1992) Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome. Cardiovasc Intervent Radiol 15:319–327\nRowell NP, Gleeson FV (2001) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev. doi:10.1002\u002F14651858.cd001316\nSchechter MM (1954) The superior vena cava syndrome. Am J Med Sci 227:46–56\nSchraufnagel DE, Hill R, Leech JA, Pare JA (1981) Superior vena caval obstruction. Is it a medical emergency? Am J Med 70:1169–1174\nSculier JP, Evans WK, Feld R, Deboer G, Payne DG, Shepherd FA, Pringle JF, Yeoh JL, Quirt IC, Curtis JE, Herman JG (1986) Superior vena caval obstruction syndrome in small cell lung cancer. Cancer 57:847–851. doi:10.1002\u002F1097-0142(19860215)57:4\u003C847:AID-CNCR2820570427>3.0.CO;2-H\nSofue K, Takeuchi Y, Arai Y, Sugimura K (2013) Life-threatening cerebral edema caused by acute occlusion of a superior vena cava stent. Cardiovasc Intervent Radiol 36:272–275. doi:10.1007\u002Fs00270-012-0421-1\nSpiro SG, Shah S, Harper PG, Tobias JS, Geddes DM, Souhami RL (1983) Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus. Thorax 38:501–505. doi:10.1136\u002Fthx.38.7.501\nStanford W, Jolles H, Ell S, Chiu LC (1987) Superior vena cava obstruction: a venographic classification. AJR Am J Roentgenol 148:259–262. doi:10.2214\u002Fajr.148.2.259\nSugawara K, Mizumoto M, Numajiri H, Ohno T, Ohnishi K, Ishikawa H, Okumura T, Sakurai H (2014) Proton beam therapy for a patient with a giant thymic carcinoid tumor and severe superior vena cava syndrome. Rare Tumors 6(2). doi:10.4081\u002Frt.2014.5177\nSundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004) Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a National Phase III Trial. J Clin Oncol 22:801–810. doi:10.1200\u002Fjco.2004.06.123\nTaguchi J, Kinoshita I, Akita H (2011) Gan to kagaku ryoho [Superior vena cava syndrome]. Cancer Chemother 38:518–523\nTanigawa N, Sawada S, Mishima K, Okuda Y, Mizukawa K, Ohmura N, Toita T, Ogawa K, Kobayashi M, Kobayashi M (1998) Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol. 39:669–674\nTimmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L (2007) Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 25:947–952. doi:10.1200\u002Fjco.2006.09.7469\nTimmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA J Am Med Assoc 303:1070–1076. doi:10.1001\u002Fjama.2010.261\nTimmerman RD, Herman J, Cho LC (2014) Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol 32:2847–2854. doi:10.1200\u002Fjco.2014.55.4675\nTrigaux JP, Van Beers B (1990) Thoracic collateral venous channels: normal and pathologic CT findings. J Comput Assist Tomogr 14:769–773\nUberoi R (2006) Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 29:319–322. doi:10.1007\u002Fs00270-005-0284-9\nWan JF, Bezjak A (2010) Superior vena cava syndrome. Hematol Oncol Clin N Am 24:501–513. doi:10.1016\u002Fj.hoc.2010.03.003\nWatkinson AF, Yeow TN, Fraser C (2008) Endovascular stenting to treat obstruction of the superior vena cava. BMJ (Clinical research ed) 336:1434–1437. doi:10.1136\u002Fbmj.39562.512789.80\nWillers H, Azzoli CG, Santivasi WL, Xia F (2013) Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 19:200–207. doi:10.1097\u002FPPO.0b013e318292e4e3\nWilson LD, Detterbeck FC, Yahalom J (2007a) Superior Vena Cava Syndrome with malignant causes. N Engl J Med 356:1862–1869. doi:10.1056\u002FNEJMcp067190\nWilson P, Bezjak A, Asch M, Barton R, Wong R, Levin W, Kane G, Kirkbride P (2007b) The difficulties of a randomized study in superior vena caval obstruction. J Thorac Oncol 2:514–519. doi:10.1097\u002FJTO.0b013e318060096b\nYamagami T, Nakamura T, Kato T, Iida S, Nishimura T (2002) Hemodynamic changes after self-expandable metallic stent therapy for vena cava syndrome. AJR Am J Roentgenol 178:635–639. doi:10.2214\u002Fajr.178.3.1780635\nYellin A, Rosen A, Reichert N, Lieberman Y (1990) Superior vena cava syndrome. The myth–the facts. Am Rev Respir Dis 141:1114–1118. doi:10.1164\u002Fajrccm\u002F141.5_Pt_1.1114\nYu JB, Wilson LD, Detterbeck FC (2008) Superior Vena Cava Syndrome: a proposed classification system and algorithm for management. J Thorac Oncol 3(811–814):8. doi:10.1097\u002FJTO.1090b1013e3181804791",{"EN":1255},"Superior vena cava syndrome (SVCS) is a relatively common sequela of mediastinal malignancies and may cause significant patient distress. SVCS is a medical emergency if associated with laryngeal or cerebral edema. The etiologies and management of SVCS have evolved over time. Non-malignant SVCS is typically caused by infectious etiologies or by thrombus in the superior vena cava and can be managed with antibiotics or anti-coagulation therapy, respectively. Radiation therapy (RT) has long been a mainstay of treatment of malignant SVCS. Chemotherapy has also been used to manage SVCS. In the past 20 years, percutaneous stenting of the superior vena cava has emerged as a viable option for SVCS symptom palliation. RT and chemotherapy are still the only modalities that can provide curative treatment for underlying malignant etiologies of SVCS. The first experiences with treating SVCS with RT were reported in the 1970’s, and several advances in RT delivery have subsequently occurred. Hypo-fractionated RT has the potential to be a more convenient therapy for patients and may provide equal or superior control of underlying malignancies. RT may be combined with stenting and\u002For chemotherapy to provide both immediate symptom palliation and long-term disease control. Clinicians should tailor therapy on a case-by-case basis. Multi-disciplinary care will maximize treatment expediency and efficacy.",{"EN":1257},"Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome",{"VOID":1259},"10.1186\u002Fs40064-016-1900-7","https:\u002F\u002Fspringerplus.springeropen.com\u002Farticles\u002F10.1186\u002Fs40064-016-1900-7",[1262,1277,1294,1309,1321,1336],{"id":1263,"sortIndex":129,"researcher":19,"roles":1264,"affiliations":1265,"properties":1274},"7dd3c0ea-5d7b-433e-ad8f-e6702db786c2",[69],[1266],{"id":19,"sortIndex":20,"affiliation":1267,"properties":19},{"id":1268,"createTime":1269,"updateTime":1269,"relativeEntities":1270,"slug":19,"properties":1271,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"dc710a88-a56a-4ce2-9dd9-f3b9733a0b72","2024-01-18T22:18:01.427+00:00",[],{"title":1272},{"VI":1273},"Dattoli Cancer Center, Sarasota, USA",{"title":1275},{"VI":1276},"Joseph Kaminski",{"id":1278,"sortIndex":20,"researcher":19,"roles":1279,"affiliations":1280,"properties":1291},"1017843c-3f91-4b17-b0d1-9e38731a12f4",[69],[1281],{"id":19,"sortIndex":20,"affiliation":1282,"properties":19},{"id":1283,"createTime":1284,"updateTime":1285,"relativeEntities":1286,"slug":1287,"properties":1288,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"64c9a772-7746-4ce7-87a8-e0911da5a096","2023-12-01T14:55:07.144+00:00","2024-09-20T09:02:31.448+00:00",[],"Department-of-Radiation-Oncology-University-of-Texas-Southwestern-Medical-Center-Dallas-USA",{"title":1289},{"VI":1290},"Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA",{"title":1292},{"VI":1293},"Christopher Straka",{"id":1295,"sortIndex":245,"researcher":19,"roles":1296,"affiliations":1297,"properties":1306},"78bb2937-cc20-4cff-a5c5-618611b6b10d",[69],[1298],{"id":19,"sortIndex":20,"affiliation":1299,"properties":19},{"id":1300,"createTime":1301,"updateTime":1301,"relativeEntities":1302,"slug":19,"properties":1303,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"8bb91ba9-d431-4d55-be42-45fff865331c","2024-01-18T22:18:01.489+00:00",[],{"title":1304},{"VI":1305},"Department of Radiation Oncology, Texas Oncology, Waco, USA",{"title":1307},{"VI":1308},"D. W. Nathan Kim",{"id":1310,"sortIndex":116,"researcher":19,"roles":1311,"affiliations":1312,"properties":1318},"77687ef4-ca0e-4a5c-9c8a-c939d9f5ce27",[69],[1313],{"id":19,"sortIndex":20,"affiliation":1314,"properties":19},{"id":1283,"createTime":1284,"updateTime":1285,"relativeEntities":1315,"slug":1287,"properties":1316,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},[],{"title":1317},{"VI":1290},{"title":1319},{"VI":1320},"James Ying",{"id":1322,"sortIndex":100,"researcher":19,"roles":1323,"affiliations":1324,"properties":1333},"e0f9f329-e2e3-4f8b-92ab-81d7c90ec259",[69],[1325],{"id":19,"sortIndex":20,"affiliation":1326,"properties":19},{"id":1327,"createTime":1328,"updateTime":1328,"relativeEntities":1329,"slug":19,"properties":1330,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"e568b4fd-d216-464a-907a-582b891cca54","2024-01-18T22:18:01.364+00:00",[],{"title":1331},{"VI":1332},"Department of Radiation Oncology, The University of Alabama Birmingham, Birmingham, USA",{"title":1334},{"VI":1335},"Christopher D. Willey",{"id":1337,"sortIndex":67,"researcher":19,"roles":1338,"affiliations":1339,"properties":1348},"e265f681-69c9-4f96-a0e3-c4c57455f883",[69],[1340],{"id":19,"sortIndex":20,"affiliation":1341,"properties":19},{"id":1342,"createTime":1343,"updateTime":1343,"relativeEntities":1344,"slug":19,"properties":1345,"entityType":79,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20},"df4755fd-4800-46e4-bf7a-80baa8c408d4","2024-01-18T22:18:01.292+00:00",[],{"title":1346},{"VI":1347},"Department of Radiation Oncology, GRU Cancer Center and Medical College of Georgia, Augusta, USA",{"title":1349},{"VI":1350},"Feng-Ming Kong",{"url":1260,"publisher":1352,"properties":1367},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1353,"slug":10,"properties":1354,"entityType":17,"verifyStatus":18,"verifyTime":19,"verifyNote":19,"syncStatus":18,"languages":19,"translateLanguages":19,"viewCount":20,"subjectFields":1358,"manageAffiliations":1359,"indexDatabases":1360,"url":19,"thumbnailPath":19,"statistic":19,"gsStatistic":19,"type":19,"analyzePriority":19},[],{"issn":1355,"title":1356,"url":1357},{"VOID":13},{"EN":10},{"VOID":16},[],[],[1361],{"id":25,"indexDatabase":1362,"url":38,"indexYears":39,"academicFieldIds":19,"indexDatabaseRanking":40},{"id":27,"createTime":28,"updateTime":29,"relativeEntities":1363,"label":1364,"description":1365,"key":35,"publicationTags":1366,"standard":19},[],{"EN":32,"VI":32},{"EN":32,"VI":34},[37],{"volume":1368,"pages":1369},{"VOID":298},{"VOID":1370},"1-13","2016-02-29"]